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The Off-Label Loophole in the
Psychopharmacologic Setting:
Prescription of Antipsychotic
Drugs in the Nonpsychotic
Patient Population
Lisa E. Smilan†
Abstract
U.S. physicians have wide discretion in treating patients with
off-label medications. Many consider off-label prescription
essential in our country’s health care system, and it is wholly
supported by FDA and federal courts. Assumptions about
physicians’ expertise, judgments, and commitments to
beneficence and nonmaleficence undergird laissez-faire policies
that allow and support physicians’ novel and innovate uses of
FDA-approved drugs for purposes and populations not studied in
original, strictly regulated clinical trials. Though sometimes
beneficial, off-label prescribing, which flourishes in privatepractice psychiatry, often harms scores of psychiatric patients.
Frequently, potential harms are insufficiently disclosed to
patients. In the public health sector, officials have begun to
identify and warn of dangers surrounding antipsychotic use in
nonpsychotic foster children. Within the government-funded
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insurance apparatus there are built-in means for checking harmful
physician practices. Such oversight mechanisms are deficient in
the private insurance sector, and absent where treatment is paid
for out-of-pocket. The Article proposes that private-practice
psychiatrists’ collective widespread “experimental” treatment of
nonpsychotic patients with antipsychotics off label resembles
clinical research without regulation or meaningful accountability.
Because harmful physician practices in the off-label
antipsychotics space are largely unchecked by state regulation
and law, action is required to protect some of our most vulnerable
patients.
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Introduction
It is notable that consent is required of participants in a
drug trial because the drug’s effects have yet to be shown,
but consent is not required for a drug prescribed in a
clinical setting for a purpose that has not been fully studied.
. . . Without a clear stance taken by the legal
establishment, the medical establishment is less able to set
up a model of best practice on this issue and has less
incentive to do so.1

While other specialists and general practice physicians are
moving towards collaborating and conferring within partnerships
1.

Zain Mithani, Informed Consent for Off-Label Use of Prescription
Medications, 14 AMA J. ETHICS 576, 578 (2012) (citing David C.
Radley et al., Off-label Prescribing Among Office-based Physicians,
166 ARCH. INTERN. MED. 1021 (2006)).
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or other business entities, the majority of office-based
psychiatrists are in practice alone. A study analyzing data from
a national survey of U.S. office-based physicians2 revealed that
private fee-for-service insurance, Medicare, and Medicaid
acceptance rates by psychiatrists were significantly lower than
acceptance rates of other specialist physicians.3 Psychiatrists
practicing alone were less likely to accept any type of insurance.4
Without input from colleagues and oversight by insurance
companies, psychiatrists are positioned to be practicing in
isolation.
Individual psychiatrists may believe they are treating
individual patients, but the collective behavior of individual
psychiatrists has led to widespread prescription of antipsychotic
drugs to classes of vulnerable patients who are not psychotic. This
may not be the intent of the independent psychiatrist, but
nonetheless it is the outcome and cause for great concern.
Widespread off-label use of antipsychotics adversely affects not
only the individual patients, but results in additional healthcare
expenditures to treat “side-effect” illnesses (including the use of
additional costly medications to treat those illnesses).5
Additionally, unnecessary antipsychotic prescription can
2.

Tara F. Bishop et al., Acceptance of Insurance by Psychiatrists and
the Implications for Access to Mental Health Care, 71 JAMA
PSYCHIATRY 176, 179 (2014).

3.

Id. By percentage, in 2009–10 the rate of psychiatrists who accepted
private fee-for-service insurance was much lower than that
representing acceptance by other specialists (55.3% versus 88.7%);
and that 2009–10 rate showed a decline of 17.0% compared to 2005–
06. The percentage of psychiatrists accepting Medicare in 2009–10
was significantly lower than other specialists (54.8% versus 86.1%),
declining by 19.5% from 2005–06. Psychiatrists’ Medicaid
acceptance rates were lower than other specialists in 2009–10
(43.1% vs. 73.0%), but remained relatively stable compared to
2005–06 rates. Id.

4.

Id. 43.0% of solo practitioners accepted private fee-for-service
insurance compared to 74.9% of those who practiced in groups;
45.0% of solo practitioners accepted Medicare compared to 69.5%
of those who practiced in groups; and 26.8% of solo practitioners
accepted Medicaid compared to 67.3% of those who practiced in
groups. Id. In 2009–10, nearly half of psychiatrists did not accept
private fee-for-service insurance, and over half did not accept either
Medicare or Medicaid. Id.

5.

See Nevena Divac et al., Second-Generation Antipsychotics and
Extrapyramidal Adverse Effects, BIOMED RES. INT’L 1, 2 (2014).
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adversely affect productivity of patients and reduce earning
potential. The Hippocratic mandate to “do no harm” is
implicated here,6 however, that mandate is sometimes distorted
by a narrow focus on the present and not the future. For example,
a “quick fix” to quell a patient’s mind or alleviate depression may
lead to a lifetime of drug-induced physical ailments.
The policy of allowing individual physicians to prescribe off
label for unapproved diseases and unapproved patient groups
derives from several assumptions about the profession, for
example, that all physicians: (1) are exceptionally intelligent and
intuitive; (2) share information and decision-making with
patients; (3) listen to patients’ concerns; (4) engage in
appropriate screenings and long-term follow-ups with patients;
(5) keep current with medical developments by reading broadly
and critically; and (6) don’t have tunnel vision. In the instance of
mental health treatment, off-label use can be particularly
troubling, especially where the psychiatrist (or general
practitioner) legally and frequently prescribes antipsychotics to
the nonpsychotic patient.
In general, the psychiatric patient group experiences a
heightened potential for vulnerability due to the nature of mental
health illnesses and the increased sense of confidentiality and
trust inherent in the psychiatrist-patient relationship. While the
mentally ill patient may need additional protections against
unsafe and ineffective off-label use of prescription drugs, the Food
and Drug Administration (FDA) takes a hands-off approach,
generally abdicating any responsibility for ensuring the welfare of
those who are prescribed approved drugs for unapproved
purposes.
This Article examines the “practice of medicine exception”
applicable in U.S. drug law that allows licensed physicians,
including psychiatrists, to write prescriptions for non-indicated
purposes and non-studied patient populations, and the various
bases and supports proffered for this system structure. Part I
considers the purposes of the Federal Food, Drug, and Cosmetic
6.

Note that a recent Medscape poll found that of respondentphysicians under age 34, 39% viewed the Oath as “very
meaningful,” whereas with respondent-physicians over age 64, 70%
said the Oath was “very meaningful.” Marcia Frellick, Youngest,
Oldest Physicians Diverge on Hippocratic Oath, MEDSCAPE (June
2, 2017), https://www.medscape.com/viewarticle/880688#vp_1
[https://perma.cc/5A5A-WENL].
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Act of 1938 and the role of physicians in the U.S. prescriptiondrug scheme. Part II provides an overview of antipsychotics. Part
III considers the prevalence of psychiatrists prescribing
antipsychotics to nonpsychotic patients, addresses the absence of
safety and efficacy studies, and proposes that psychiatrists are
legally conducting quasi “clinical drug trials” in the collective
treatment of individual patients. Part IV contemplates who, if
anyone or any entity, is willing to protect our vulnerable
psychiatric patients (especially multiply vulnerable psychiatric
patients), and explores how certain patient groups are “legally
safe” specimens for informal “clinical drug trials.” It also reviews
unsuccessful past attempts by FDA and Congress to close the offlabel loophole, proposes putting the public health before the
health care professional, and considers what might be done to
bring about change and reform. The Article concludes with
thoughts on future efforts that might protect nonpsychotic
psychiatric patients from potentially harmful antipsychotics not
proved to be safe or effective in this population.

I.

Purposes of FDCA and Role of Physicians

The Federal Food, Drug, and Cosmetic Act of 1938 (FDCA)7
regulates drug quality, providing that “no new drug can be
marketed until proved safe for use under the conditions described
on the label and approved by the FDA.”8 The Kefauver-Harris
Amendment of 1962, also referred to as the Drug Efficacy
Amendment, added the requirement that a drug not only must
be safe, but it must be effective. The 1962 amendment also
augmented subject protections in clinical drug investigations by
requiring subjects’ informed consent and the reporting of adverse
reactions related to study drugs.9 Several amendments have been
enacted since, but none that alter these essential protections.
A. Requirements for New Drugs: Safety and Efficacy

For the purpose of protecting “the nation from harmful or
worthless drugs and devices,” FDA has been charged by Congress
to ensure that only drugs, devices and biologics that have been
7.

21 U.S.C. §§ 301 et seq. (2018).

8.

RICHARD R. ABOOD & DAVID B. BRUSHWOOD, PHARMACY PRACTICE
AND THE LAW 27 (1994).

9.

Id. at 28.
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reviewed and approved by FDA for both safety and efficacy may
be sold in the United States.10 Sponsors file applications for an
Investigational New Drug (IND) with FDA, and the agency
ultimately decides the types of clinical trials that are necessary to
prove that the new treatment is safe and effective for treating a
particular medical ailment in a particular patient population.11
FDA’s rules protecting human subjects in clinical trials can be
found in two locations: (1) 21 C.F.R. Part 56, relating to
Institutional Review Boards (IRBs); and (2) 21 C.F.R. Part 50,
relating to informed consent.12 Under FDA regulations, IRBs
assist the agency with human-subjects protection by reviewing
and monitoring clinical trials within FDA’s jurisdiction.13
Once completed, results from an FDA-approved study must
be submitted to an expert panel, which then tells FDA whether
or not the drug has been demonstrated to be safe and effective.14
FDA’s “stamp of approval” extends only to the specified medical
purpose and the specified population for which the drug, device,
or biologic was studied. After approval, in numerous instances,
medical experts have discovered that treatments approved for one
indication “may also serve other valuable medical purposes.”15
FDA views its mandate as ensuring the safety and efficacy of
drugs and devices under conditions set forth by the manufacturer
10.

Coleen Klasmeier & Martin H. Redish, Off-Label Prescription
Advertising, The FDA and the First Amendment: A Study in the
Values of Commercial Speech Protection, 37 AM. J. L. & MED. 315
(2011) (referencing 21 U.S.C. §§ 335(a), 360(k), 360(e) (2018)); see
CARL H. COLEMAN ET AL., THE ETHICS AND REGULATION OF
RESEARCH WITH HUMAN SUBJECTS 151 (2nd ed. 2015).

11.

COLEMAN ET AL., supra note 10, at 251.

12.

Id.

13.

Richard M. Cooper & Benjamin M. Greenblum, The Philosophy of
Food and Drug Law, in A PRACTICAL GUIDE TO FDA’S FOOD AND
DRUG LAW AND REGULATION 67, 79 (Kenneth R. Piňa & Wayne L.
Pines eds. 2017).

14.

COLEMAN ET AL., supra note 10, at 151.

15.

Klasmeier & Redish, supra note 10, at 315 n. 2 (citing John E.
Osborn, Can I Tell You the Truth? A Comparative Perspective on
Regulating Off-Label Scientific and Medical Information, 10 YALE
L. HEALTH POL’Y L. & ETHICS 299, 304 (2010) (“[I]n some
therapeutic areas off-label uses are the customary, preferred
treatments and are publicly declared to be such on patient
advocacy group websites and elsewhere.”)).
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in the IND study, not whether a medical treatment is safe for any
use for which it may actually be prescribed.16 But this “any use”
permission allows for the possibility that using an approved drug
in an unapproved manner may result in “worthless or even
dangerous” medication of a patient.17 Logic would instruct that if
FDA is charged with protecting the public from harmful and
useless drugs, medical devices, and biologics, then the agency
should require testing and approval for any use that is outside
the scope of the IND study.18 While the approval process for
drugs, devices, and biologics determines the safety for human use
under particular parameters, uses for completely different
purposes and populations could give rise to public safety issues.19
B. Off-Label Prescription

Off-label use generally refers to three things: (1) the practice
of a physician prescribing a legally manufactured drug for
purposes other than those indicated on that drug’s FDAmandated labeling;20 (2) using a different method of applying the
treatment and prescribing a drug, device, or biologic to patient
groups other than those approved by FDA;21 and (3) prescriptions
for drug dosages that are different from the approved labelrecommended dosage or for time periods exceeding the labelrecommended usage.22
16.

Carol Berry, The Dividing Line Between the Role of the FDA and
the Practice of Medicine: A Historical Review and Current
Analysis, at 33–34 (1997), available at http://nrs.harvard.edu/urn3:HUL.InstRepos:8846812
[https://perma.cc/E98C-QCUE]
(unpublished Third Year paper).

17.

Klasmeier & Redish, supra note 10, at 316.

18.

Berry, supra note 16, at 35.

19.

Id. at 38–39.

20.

Ramune E. Barkus & Armand Derian, Physician and Hospital
Liability in Drug and Medical-Device Litigation, in DRUG INJURY:
LIABILITY, ANALYSIS AND PREVENTION 861, 863 (James T.
O’Donnell ed., 3d ed. 2012).

21.

Richard C. Ausness, There’s Danger Here, Cherie!: Liability For
The Promotion and Marketing of Drugs and Medical Devices for
Off-Label Uses, 73 BROOK. L. REV. 1253, 1254 (2008) (citing Lars
Noah, Constraints on the Off-Label Uses of Prescription Drug
Products, 16 J. PROD. & TOXICS LIAB. 139, 141 (1994)).

22.

Id. (citing Elizabeth A. Weeks, Is It Worth the Trouble? The New
Policy on Dissemination of Information On Off-Label Use Under
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The accepted practice of off-label prescribing for nonindicated purposes or populations both undermines FDA’s
authority and mission, as well as deters pharmaceutical
manufacturers from seeking on-label FDA approval for purposes
the manufacturer could foresee as a widespread alternative use.23
Proponents of off-label uses argue that what is “safe” and
“effective” should depend partly on a physician’s judgment and
preferences, and not exclusively on objective fact.24 These
proponents state—as though inherently a positive proposition—
that “[o]ff-label prescribing offers patients and doctors a choice
between the judgements of the medical and scientific
communities” and those of FDA.25 But FDA’s purpose is to
protect the American public from unsafe and ineffective drugs,
and the agency requires a certain level of proof before initial
approval of a drug. In turn, the off-label option may cast the
initial FDA approval as a mere “wedge to permit the industry’s
equivalent of the Wild West, where the rule of law was seen only
rarely.”26
The American public largely is unaware of the prevalence of
off-label prescribing.27 Despite the ubiquitous nature of off-label
uses, a 2016 Consumer Reports survey revealed that ninety-four
percent of Americans could not recall ever having been informed
by a doctor that their prescriptions were for a purpose not
approved by FDA and sixty-three percent said that they would
refuse a doctor-prescribed drug that was not FDA-approved for
their particular ailment.28 So, while most patients would want to
the Food and Drug Administration Modernization Act of 1997, 54
FOOD & DRUG L. J. 645, 647 (1999)).
23.

Klasmeier & Redish, supra note 10, at 316.

24.

Alexander T. Tabarrok, Assessing the FDA Via the Anomaly of
Off-Label Drug Prescribing, 5 THE INDEP. REV. 25, 34 (2000).

25.

Id.

26.

Klasmeier & Redish, supra note 10, at 316.

27.

Margaret Z. Johns, Informed Consent: Requiring Doctors to
Disclose Off-Label Prescriptions and Conflicts of Interest, 58
HASTINGS L. J. 967, 979 (2007).

28.

Christopher Robertson, National Survey Suggests that Off-Label
Status is Material to Informed Consent, HARV. BLOG (Jan. 25,
2017), http://blogs.harvard.edu/billofhealth/2017/01/25/nationalsurvey-suggests-that-off-label-status-is-material-to-informedconsent/ [https://perma.cc/65Q3-TYTY].
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know that their prescriptions are not for FDA-approved uses, this
information is often withheld.29 In contrast to FDA’s requirement
of informed, written consent for all phases of IND clinical trials,
“there is no FDA requirement of informed consent to off-label
prescriptions which [ ] FDA does not regulate at all.”30
There are many reasons why a physician might prescribe a
drug off label. For example, there may be no FDA-approved drug
to treat a particular ailment.31 With regard to pediatric patients,
only twenty-to-thirty percent of FDA-approved drugs are labeled
for pediatric use:32 Without the off-label option, many pediatric
diseases would go untreated.33 In remarks on the Food and Drug
Administration Modernization and Accountability Act of 1997,
one Senator stated: “[a]s much as 90 percent of all of the uses of
drugs in oncology or the treatment of cancer are used in what is
called an off-label or extra-label manner.”34
However, skepticism about the appropriateness of off-label
uses finds support in a 2006 Archives of Internal Medicine survey
that reviewed 150 million off-label prescriptions in the United
States, finding that “73 percent had little to no scientific
backing.”35 That study found that “off-label medication use is
common in outpatient care, and most occurs without scientific
support.”36 Without safety and efficacy studies, off-label uses of
prescription drugs “can be risky, and some off-label uses have
29.

Id.

30.

Johns, supra note 27, at 979.

31.

Marisa A. Trasatti & Lindsey N. Lanzendorfer, Defending Products
Liability Suits Involving Off-Label Use: Does the Learned
Intermediary Doctrine Apply?, 62 FED’N DEF. CORP. COUNS. Q. 2,
5 (2011), available at https://cdn.ymaws.com/thefederation.siteym.com/resource/resmgr/docs/Quarterly/Archive/V62N1_Coverto-Cover.pdf [https://perma.cc/GM3Z-B5QC].

32.

Id. at 5.

33.

Id.

34.

143 CONG. REC. S8165 (daily ed. July 28, 1997) (statement of Sen.
Frist).

35.

Mithani, supra note 1, at 577 (citing David C. Radley et al., OffLabel Prescribing Among Office-Based Physicians, 166(9) ARCH.
INTERN. MED. 1021 (2006)); see also Johns, supra note 27, at 969;
Wendy Teo, FDA and the Practice of Medicine: Looking at OffLabel Drugs, 41 SETON HALL LEGIS. J. 305, 311 (2017).

36.

Johns, supra note 27, at 969.
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turned out to be very dangerous.”37 For example, in the case of
the drug Fenfluramine, from the mid-to-late-1990s doctors wrote
eighteen million prescriptions for its off-label use for weight loss
before it was discovered that the drug had caused almost three
hundred thousand people to suffer heart-valve damage.38 Patients
actually may be exposed to more risk after a drug, device, or
biologic is FDA-approved, as opposed to still under investigation,
because during clinical trials on human subjects, FDA imposes
strict informed consent requirements.39
While the Federal Government could attempt to circumvent
this potential danger by imposing a blanket prohibition against
all off-label uses, and instead mandate that drugs, devices, and
biologics be granted FDA approval for each and every use by each
and every population, this alternative has its own host of
problems.40 Such a ban could result in potentially beneficial uses
for some of our most serious diseases being tied up for years in
the FDA-approval process. Another possibility would be that
pharmaceuticals and device manufacturers would simply walk
away, deciding that the costs outweigh any benefits that
manufacturers could realize through obtaining new and separate
approvals for each type of off-label use.41 Terminally ill patients,
for example, might be left with no treatment options at all.
There are arguments for both sides. Distinctions can be made,
however, when talking about incurable, life-threatening illnesses,
versus the use of mind-altering antipsychotics in the nonpsychotic
patient population. Even if the psychiatric patient is severely
depressed and suicidal, for example, alternative measures could
be taken—even in emergency situations—to prevent death and
stabilize the patient without introducing antipsychotics into the
37.

Kaspar J. Stoffelmayr, Comment, Products Liability and “OffLabel” Uses of Prescription Drugs, 63 U. CHI. L. REV. 275, 280
(1996) (footnote omitted).

38.

Mithani, supra note 1, at 577 (citing Steven R. Salbu, Off-Label
Use, Prescription, and Marketing of FDA-Approved Drugs: An
Assessment of Legislative and Regulatory Policy, 51 FLA. L. REV.
181, 203 (1999) and Molly Sachdev et al., Effect of FenfluramineDerivative Diet Pills on Cardiac Valves: A Meta-Analysis of
Observational Studies, 144 AM. HEART J. 1071 (2002)).

39.

Berry, supra note 16, at 45 (citing 21 U.S.C. § 355(i)(3) (2018)).

40.

Klasmeier & Redish, supra note 10, at 316.

41.

Id.
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already frail or troubled mind. Such alternatives include longer
inpatient stays and more psychosocial interventions. In extreme
situations of treatment-resistant depression, electroconvulsive
therapy under anesthesia may be another effective intervention.42
These suggested alternatives, however, require more time and
expense compared to patients swallowing pills widely available as
cheap generics. If time and cost constraints prohibit alternative
treatments, another possibility is to continue allowing use of
antipsychotics in the nonpsychotic patient population under
emergency circumstances, but imposing limits on the duration of
such treatment. Especially in the circumstance of the
nonpsychotic patient taking antipsychotic drugs on a long-term
basis, side effects can be deleterious, even deadly.
C. The “Practice of Medicine Exception”
1.

FDA Deference to Physicians

Policy justifications for off-label prescribing rest on the fact
that FDA does not regulate the practice of medicine. Again, once
a drug is approved by FDA, use of that drug is not restricted to
uses indicated on FDA-mandated labeling.43 FDA has always
maintained that it will not interfere with a physician’s
autonomy,44 and that the Practice of Medicine Exception prevents
the agency from regulating a physician’s “unapproved use of an
approved drug” within the confines of clinical practice.45 In 1998,
FDA issued guidance specifically addressing off-label use of drugs.
In that paper, FDA stated that the patient’s bests interests and
good medical practice require that physicians have freedom to
decide which prescription drugs, biologics, and devices to use, and
such determination should be based on the physician’s “best
42.

Kristina Thurin et al., How Neuroscience is Informing Treatments:
Ethical Issues, 17 FOCUS 35, 37 (2019) (“[T]he notion of ECT
causing brain damage is a myth, with no scientific evidence to
support it” and “[r]ecent studies show . . . that ECT is associated
with increases in brain volume in regions such as the hippocampus
and with increased integrity of connections between brain
region[s].”).

43.

Barkus & Derian, supra note 20, at 863.

44.

Teo, supra note 35, at 305.

45.

Berry, supra note 16, at 35–36; C Lee Ventola, Off-Label Drug
Information: Regulation, Distribution, Evaluation, and Related
Controversies, 34 PHARM. & THERAPEUTICS 436 (2009).
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knowledge and judgment.”46 FDA continued that when
prescribing for a use not indicated on approved labeling, a
physician must be well informed, base the off-label prescription
on a firm scientific rationale and medical evidence, and then
maintain records documenting the off-label use and its effects on
the patient.47 Further, an IND or Investigational Device
Exemption (IDE) are not required if the off-label use is pursuant
to the “practice of medicine.”48 In 1999, FDA formally amended
its regulations, clarifying decidedly, as follows: “(d) Unlabeled
indication. This part does not apply to the use in the practice of
medicine for the unlabeled indication of a new drug product
approved under part 314 or of a licensed biological product.”49
This was one more signal that FDA was comfortable with the
status quo, and would not be interjecting itself into the physicianpatient relationship.
The federal government’s position is clear: FDA regulations
“do not restrict a physician’s ability to prescribe drugs for off
label uses,”50 and federal courts reiterate this stance, without
question.51 For example, in Buckman Co. v. Plaintiffs’ Legal
Comm.,52 the U.S. Supreme Court noted that once a drug receives
FDA approval for any use, physicians may use legally marketed
drugs in any way they believe will best serve their patients, and
described off-label prescribing as “an accepted and necessary
corollary” of FDA’s “mission to regulate in this area without

46.

COLEMAN ET AL., supra note 10, at 167.

47.

Id.

48.

Id.

49.

Klasmeier & Redish, supra note 10, at 323 (citing 21 C.F.R. §
312.2(d) (2019)).

50.

Trasatti & Lanzendorfer, supra note 31, at n. 9 (citing Ausness,
supra note 21, at n. 7).

51.

See, e.g., Buckman Co. v. Plaintiffs’ Legal Comm., 121 S.Ct. 1012,
1018 (2001); United States ex rel. Polansky v. Pfizer, Inc., 822 F.3d
613, 615 (2nd Cir. 2016) (quoting U.S. v. Caronia, 703 F.3d 149,
153 (2nd Cir. 2012) for the statement that “[o]nce FDA-approved,
prescription drugs can be prescribed by doctors for both FDAapproved and unapproved uses; the FDA generally does not
regulate how physicians use approved drugs.”).

52.

Buckman, 121 S.Ct. at 1018–19 (2001).
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directly interfering with the practice of medicine.”53 In United
States v. Evers,54 the Fifth Circuit stated that though FDA “‘was
obviously intended to control the availability of drugs for
prescribing by physicians,’ it ‘was not intended to regulate the
practice of medicine.’”55 And in discussing the topic in United
States v. Regenerative Sciences,56 the D.C. District Court noted
that FDA did not disagree with the proposition that “Congress
has left the practice of medicine to the States to regulate.”57
Aside from the federal-state debate, long included in
arguments that practitioners should control medical practice is
the assertion that when government at any level—federal, state
or local—limits practitioner discretion, this negatively effects the
quality of medical care.58 Off-label drug prescription and use is
considered by some “an important part of mainstream, legitimate
medical practice.”59 Leaders in medicine assert, rightly so, that it
would constitute medical malpractice if, in some instances, a
physician failed to use a drug in an off-label manner.60
It seems rather illogical that FDA’s responsibility to
safeguard the public from unsafe use of drugs has no overlap with
the physician’s right to prescribe an approved medication off label
within the practice of medicine.61 Yet, the only substantial limits
on a physician’s practice of medicine are those imposed by state
53.

Trasatti & Lanzendorfer, supra note 31, at n.11 (citing Buckman,
121 S.Ct. at 1018).

54.

United States v. Evers, 643 F.2d 1043, 1048 (5th Cir. 1981).

55.

Patricia J. Zettler, Toward Coherent Federal Oversight of
Medicine, 52 SAN DIEGO L. REV. 427, 430 (2015) (citing Evers, 643
F.2d at 1048); see also Teo, supra note 35, at 324.

56.

U.S. v. Regenerative Sciences, LLC, 878 F. Supp. 2d 248, 255 (D.
D.C. 2012), aff’d, 741 F.3d 1314–15 (D.C. Cir. 2014).

57.

Zettler, supra note 55, at 430 (citing Regenerative Sciences, 878 F.
Supp. 2d at 255).

58.

Id. at 437 (citing, cf., JONATHAN OBERLANDER, THE POLITICAL LIFE
MEDICARE 22 (2003) for the statement that “the American
Medical Association lobbied against government health insurance
in 1949 by arguing that it would ‘inevitably erode the quality of
medical care by giving the government [rather than physicians]
control over medical services.’”).

OF

59.

Stoffelmayr, supra note 37, at 276.

60.

Id.

61.

Teo, supra note 35, at 306.
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law regarding medical licensure and malpractice and those set by
third-party payors for reimbursement standards.62 But how,
exactly, is “the practice of medicine” defined? One scholar poses
and responds to the question aptly: “Is the ‘practice of medicine’
whatever . . . physicians say it is, or is it a question of how to
properly treat patients? . . . If it is the latter, then in the name
of safeguarding the public health, perhaps there is some
foundation for the government to intervene and impose
regulations.”63 In The Belmont Report, the 1979 report of the
National Commission for the Protection of Human Subjects of
Biomedical and Behavioral Research, the Commission drew
distinctions between medical research and medical practice, the
latter defined as “interventions that are designed solely to
enhance the wellbeing of an individual . . . and that have a
reasonable expectation of success.”64 Our modern definitions of
“the practice of medicine” are derived from statutory language
and court decisions, and among the states there are various
interpretations65 that fluctuate over time.66 An unequivocal
determination of the scope of “the practice of medicine exception”
has never been established,67 and often depends on the
stakeholders involved in setting the parameters.68

62.

Cooper & Greenblum, supra note 13, at 79.

63.

Teo, supra note 35, at 306.

64.

NAT’L COMM’N FOR THE PROTECTION OF HUM. SUBJECTS OF
BIOMEDICAL AND BEHAV. RES., THE BELMONT REPORT: ETHICAL
PRINCIPLES AND GUIDELINES FOR THE PROTECTION OF HUMAN
SUBJECTS OF RESEARCH 2 (1978), available at https://www.
hhs.gov/ohrp/sites/default/files/the-belmont-report-508c_FINAL
.pdf [https://perma.cc/Z7S7-USU4] [hereinafter THE BELMONT
REPORT]; see also Nancy King, The Line Between Clinical
Innovation and Human Experimentation, 32 SETON HALL L. REV.
573, 573 (2002) (footnote omitted).

65.

Zettler, supra note 55, at 435.

66.

Wendy Teo notes varying descriptions over time, from the “art of
healing” to the administration of drugs or performance of surgery.
“It is difficult to reach a uniform position on certain activities, and
states and courts have also grappled with defining and delineating
the boundaries of the practice of medicine.” Teo, supra note 35, at
306.

67.

Berry, supra note 16, at 12.

68.

Zettler, supra note 55, at 435.
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Given the differences in statutory definitions and language,
state courts understandably reach divergent conclusions when
viewing similar activities and determining, for example, whether
or not medical malpractice has been proven.69 However, there are
general similarities in state statutes and court determinations
regarding what constitutes “the practice of medicine,” most
including two physician activities: (1) the diagnosis of a disease,
condition or injury, and (2) the prescribing, administration or
provision of treatment for a disease, condition or injury.70
Although there are nuances in how it is defined, the Practice of
Medicine Exception appears to create a loophole that allows
innovation and experimentation with little-to-no out-of-pocket
cost to the drug manufacturer, and a huge risk reduction relating
to the manufacturer’s potential liability.
2.

Legislative Intent Underpins “Practice of Medicine Exception”

The FDCA does not explicitly support FDA’s stance on not
regulating the practice of medicine; instead, “FDA’s deference to
physicians is borne from Congressional intent.”71 Debates
preceding enactment of the FDCA make clear that Congress
never intended to regulate the practice of medicine.72 Considering
that legislative history, the U.S. Supreme Court has stated that
“FDA’s mission [is to] . . . regulate . . . without directly
interfering with the practice of medicine.”73 During congressional
hearings in 1934, the medical profession expressed concern that
the FDCA would interfere with the “prerogatives of the doctor.”74
69.

Id. at 435–36.

70.

Id. at 436; see also Teo, supra note 35, at 307 n.5 (citing Lars Noah,
Ambivalent Commitments to Federalism in Controlling the Practice
of Medicine, 53 KAN. L. REV. 149, 162 (2004) and Cynthia Marietta
& Amy L. McGuire, Direct-to-Consumer Genetic Testing: Is It the
Practice of Medicine?, 37 J. L. MED. & ETHICS, 369, 371 (2009)).

71.

Teo, supra note 35, at 307.

72.

Id. at 308 (citing ROBERT P. BRADY, FUNDAMENTALS OF LAW &
REGULATION: AN IN-DEPTH LOOK AT FOOD & DRUG
ADMINISTRATION MODERNIZATION ACT 423–24 (David G. Adams &
Richard M. Cooper eds., 1st ed. 1997)).

73.

Buckman Co. v. Plaintiffs’ Legal Comm., 121 S.Ct. 1012, 1018
(2001); see also Teo, supra note 35, at 308 n. 7.

74.

Berry, supra note 16, at 4 (citing 78 CONG. REC. NO. at 2728
(1934)).
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Senator Royal Copeland, also a homeopathic physician and strong
proponent of the legislation, stated that “this bill makes certain
that the medical practitioner shall not be interfered with in his
practice.”75
Amendments to the statutory language prior to the FDCA’s
passage likewise show Congress’s intent not to interfere with the
practice of medicine: “Initially section 321(b) of the 1938 Act,
defining the term ‘drug,’ contained language stating that it was
not intended ‘for the regulation of the legalized practice of the
healing art.’”76 In 1951, the Durham-Humphrey Amendment to
the FDCA did not effect any changes in the practice of medicine
exception.77 The amendment actually exempted prescription
drugs from section 352(f)’s requirements, giving physicians
primary responsibility of informing patients as to directions for
use and warnings about misuse.78 In 1962, Congress reiterated
that FDA was not to interfere with the practice of medicine.79 In
Section 214 of the 1997 Food and Drug Administration

75.

Id. at n.15 (citing Hutt, Regulation of the Practice of Medicine
under the Pure Food and Drug Laws, 33 Q. BULL. ASS’N OF FOOD
& DRUG OFF. NO.1, at 15 (1969)).

76.

Id. at 4–5 n.18, (citing H. R. REP. NO. 2755, at 5 (1936)); See also
Chaney v. Heckler, 718 F.2d 1174, 1180 n.13 (1983), rev’d 470 U.S.
821 (1985) (quoting S. REP. NO. 361, 74th Cong. (1st Sess. 1935);
S. REP. NO. 646, 74th Cong. (1st Sess. 1935) and Pharmaceutical
Mfrs Ass’n, 484 F. Supp. 1179, 1184 (D. Del. 1980)).

77.

Id. at 7.

78.

Id. at n. 28 (citing Pharmaceutical Mfrs. Ass’n v. Food & Drug
Admin, 484 F. Supp. 1179, 1185 (D. Del. 1980) (citing Hearings on
H.R. 3298 Before the House Committee on Interstate and Foreign
Commerce, 82nd CONG. 1st Sess. 20–21 (1951) (remarks of Fed.
Sec. Admin. Oscar Ewing)).

79.

Teo, supra note 35, at 308 n. 8 (citing Pub. L. No. 87-781, 76 Stat.
780 (codified in scattered sections of 21 U.S.C.); Lars Noah,
Ambivalent Commitments to Federalism in Controlling the Practice
of Medicine, 53 U. KAN. L. REV. 149, 173 n. 99 (2004)
(“[T]he . . . [Act] should not interfere with the professional function
of the physician. FDA clearance would assure physicians that a
drug effectively produces certain physiological actions, but the
physician, not the FDA, would determine whether these specific
physiological effects would be useful or beneficial with respect to
particular patients”).
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Modernization Act,80 Congress directed that “nothing in [the
FDCA] shall be construed to limit or interfere with the authority
of a healthcare practitioner to prescribe or administer any legally
marketed device to a patient for any condition or disease within
a legitimate health care practitioner-patient relationship.”81 The
Food and Drug Administration Amendments Act of 200782 states
that “nothing in this section shall be construed to . . . limit the
practice of medicine.”83 Clearly, deference to physicians is a
longstanding theme throughout the various iterations of U.S.
Food and Drug law.
Other U.S. health care laws likewise confer wide latitude to
the medical profession in controlling the practice of medicine, for
example, laws relating to Medicare, fertility, and drug addiction
treatment.84 Even after a public health emergency, when drafting
80.

Food and Drug Administration Modernization Act of 1997, Pub. L.
No. 105-115, § 214, 111 Stat. 2296 (codified at 21 U.S.C. § 396).

81.

Teo, supra note 35, at 308 n. 9 (citing Pub. L. No. 105-115, § 214,
111 Stat. 2296, 2348); see also Buckman Co. v. Plaintiffs’ Legal
Comm., 121 S.Ct. 1012, 1018 (2001) (“Indeed, a recent amendment
to the FDCA expressly states in part that ‘[n]othing in this chapter
shall be construed to limit or interfere with the authority of a health
care practitioner to prescribe or administer any legally marketed
device to a patient for any condition or disease within a legitimate
health care practitioner-patient relationship’.”).

82.

Food and Drug Administration Amendments Act of 2007, Pub. L.
No. 110-85, § 1111(d), 121 Stat. 823 (2007) (codified at 42 U.S.C.
§ 247d-5a(d)).

83.

Teo, supra note 35, at 308 n.10 (citing Food and Drug
Administration Amendments Act of 2007, Pub. L. No. 110-85,
§ 1111(d), 121 Stat. 823, 976 (2007).)

84.

Id. at n.11 (citing Health Insurance for the Aged Act, Pub. L. No.
89-97, § 102(a), 79 Stat. 290, 291 (1965) (codified at 42 U.S.C.
§ 1395) (“Nothing in [the Medicare statute] shall be construed to
authorize any Federal officer or employee to exercise any
supervision or control over the practice of medicine.”)); Fertility
Clinic Success Rate and Certification Act of 1992, Pub. L. No. 102493 § 3(i)(1), 106 Stat. 3146, 3149 (1992) (codified at 42 U.S.C.
§ 263a-2(i)(1)) (“In developing the [federal embryo laboratory]
certification program, the [Department of Health and Human
Services] may not establish any regulation, standard, or
requirement which has the effect of exercising supervision or control
over the practice of medicine in assisted reproductive technology
programs.”); To Amend the Public Health Service Act with
Respect to Children’s Health, Pub. L. No. 106-310, § 3502, 114
Stat. 1222, 1226 (codified at 21 U.S.C. § 823(g)(2)(H)(i)) (“Nothing
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the Drug Quality and Security Act of 2013,85 Congress expressed
concern about encroaching on state regulation of medical
practice.86 This was a measure aimed at remedying FDA’s limited
authority to regulate compounding pharmacies following the fatal
debacle involving a fungal meningitis outbreak traced to
compounded lots of injectable glucocorticoid methylprednisolone
acetate, produced by the Massachusetts-based New England
Compounding Center.87 A proponent of the 2013 law, Senator
Tom Coburn, emphasized that the Practice of Medicine remained
in the ambit of state regulators, assuring that “‘the art and
science of medicine would not be impeded’” by FDA.88
D. Physicians Regulated by State Law

States regulate medical practice under their police powers,
while the federal government regulates medical products.89 FDA
has been clear that it does not and will not regulate the practice
in such regulations or practice guidelines may authorize any
Federal official or employee to exercise supervision or control over
the practice of medicine or the manner in which medical services
are provided.”)).
85.

Zettler, supra note 55, at 430 (citing Title I of the Drug Quality
and Security Act of 2013, Pub. L. No. 113-54, 127 Stat. 587 (2013),
which addresses drug compounding; Title II of the act is intended
to improve the security of the drug supply chain).

86.

Note that state regulation is actually carried out by state medicallicensing boards, which are themselves controlled by physicians. So,
in this context, state regulation equals self-regulation. See CARL
ELLIOTT, WHITE COAT, BLACK HAT: ADVENTURES ON THE DARK
SIDE OF MEDICINE at xi (2010).

87.

Kevin Outterson, Regulating Compounding Pharmacies after
NECC, 367 NEW ENG. J. MED. 1969, 1969 (2012).

88.

Zettler, supra note 55, at 430–31, 443 (citing 159 CONG. REC.
S8029- 06 (Nov. 14, 2013) (statement of Sen. Coburn)) (“[t]he
Social Security Amendments of 1954, for example, provided that
‘[n]othing in this subchapter shall be construed as authorizing the
Commissioner of Social Security or any other officer or employee of
the United States to interfere in any way with the practice of
medicine’; The Medicare statute, the Fertility Success Rate and
Certification Act of 1992; the Food and Drug Administration
Modernization Act of 1997; the Drug Addiction Treatment Act of
2000; and the Food and Drug Administration Amendments Act of
2007 each included a provision with similar language.”).

89.

Id. at 430 (citing Dent v. West Virginia, 129 U.S. 114, 122–23, 128
(1889)).
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of medicine, and that the FDCA is not a source of physician
liability for harms arising from a physician’s off-label
prescriptions.90 However, physicians are not exempt from liability
arising from prescribing drugs off label.91 Theoretically, remedies
are available at the state level.
Medical malpractice insurance is costly, and medical
literature cautions physicians that prescribing medications for offlabel use has resulted in greater malpractice risk.92 In order to
preemptively reduce liability risks, the prudent physician would
(1) remain abreast of news and developments relating to
medications and their uses, (2) keep literature files relating to offlabel uses, (3) inform and emphasize to the patient that the
proposed treatment involves an off-label use, and (4) continually
document the patient’s informed consent.93 Yet, in the context of
mental health medical malpractice, the tort system is far from
perfect due to power differentials between mentally ill patients
and their psychiatrists.94 Thus, the tort system cannot adequately
regulate this space.
However, in instances where physicians fail to meet their
obligations by inappropriately prescribing a medication, the
patient’s malpractice claims could sound in negligence (or in
unusual circumstances strict liability) where warnings in the
Physician Desk Reference or in the drug’s package insert were

90.

Katherine A. Helm, Protecting Public Health from Outside the
Physician’s Office: A Century of FDA Regulation from Drug Safety
Labeling to Off-Label Drug Promotion, 18 FORDHAM INTELL. PROP.,
MEDIA & ENT. L. J. 116, 167 (2007).

91.

Id.

92.

James O’Reilly & Amy Dalal, Off-Label or Out of Bounds?
Prescriber and Marketer Liability for Unapproved Uses of FDAApproved Drugs, 12 ANN. HEALTH L. 295, 319 (2003) (footnote
omitted).

93.

Id.

94.

Hannah Martens & Timothy Brown, Trusting Oneself and Others:
Relational Vulnerability and DBS for Depression, 9 AM. J.
BIOETHICS NEUROSCIENCE 226 (2018) (“[T]he patient’s active
depressive symptoms, lesser knowledge about the [treatment], and
lesser understanding of possible treatment alternatives produce a
problematic power differential between the patient and their
doctor.”).
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disregarded.95 Liability might also arise where a physician failed
to obtain patient informed consent.96 Laws vary from state to
state, and what is negligent practice in one jurisdiction may be
acceptable practice in another. A further complication, concepts
of informed consent vary based on jurisdiction,97 and, in some
states, courts have found that nothing obliges a physician to
disclose the off-label use at all.98
1.

Strict Liability and Negligence

While FDA has at least once asserted that it retains
jurisdiction to regulate off-label prescription use,99 it has most
often taken the position that state tort liability is the best means
of controlling off-label uses.100 The idea is that in prescribing

95.

O’Reilly & Dalal, supra note 92, at 317 (footnote omitted); See
Amy E. Todd, No Need for More Regulation: Payors and Their
Role in Balancing the Cost and Safety Considerations of Off-Label
Prescriptions, 37 AM. J. L. & MED. 422, 424 (2011) (citing James
B. Riley, Jr. & P. Aaron Basilius, Physicians’ Liability for OffLabel Prescriptions, 6 HEMATOLOGY & ONCOLOGY NEWS & ISSUES
24, 26 (2007)); see also Barbara Marticelli McGarey,
Pharmaceutical
Manufacturers
and
Consumer-Directed
Information—Enhancing the Safety of Prescription Drug Use, 34
CATHOLIC U. L. REV. 148 (1984).

96.

Amy E. Todd, No Need for More Regulation: Payors and Their
Role in Balancing the Cost and Safety Considerations of Off-Label
Prescriptions, 37 AM. J. L. & MED. 422, 424 (2011) (footnotes
omitted).

97.

Mithani, supra note 1, at 579 (citing generally S. WEAR, INFORMED
CONSENT: PATIENT AUTONOMY AND PHYSICIAN BENEFICENCE
WITHIN CLINICAL MEDICINE (1993)).

98.

Todd, supra note 35, at 424 (citing Ausness, supra note 21, at 1253;
Margaret Z. Johns, Informed Consent: Requiring Doctors to
Disclose Off-Label Prescriptions and Conflicts of Interest, 58
HASTINGS L. J. 967 (2007)); see also Klein v. Biscup, 673 N.E.2d
225, 231 (Ohio App. 8 Dist. 1996).

99.

Stoffelmayr, supra note 37, at 279 n. 26; cf. Klasmeier & Redish,
supra note 10, at 316 (“In any event, under the current regulatory
framework, the FDA asserts that it lacks legal authority to restrict
the ability of doctors to prescribe drugs or devices for off-label
uses.” The latter is overwhelmingly the prevailing view.).

100. Stoffelmayr, supra note 37, at 279 n. 25, (citing 48 Fed. Reg. 26,720,
FDA, Legal Status of Approved Labeling for Prescription Drugs;
Prescribing for Uses Unapproved by the Food and Drug
Administration, 37 Fed. Reg. 16,503 (1972); and Use of Approved
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antipsychotic or other drugs off label, psychiatrists may expose
themselves to negligence liability by not fulfilling duties such as
obtaining adequate medical and psychiatric histories, physical
examinations, and laboratory tests.101 Further failures of
obligations arise when a physician prescribes a drug where
indication is lacking or a contraindication is present; prescribes
an improper dosage or for an unwarranted duration; or fails to
recognize, monitor or treat side effects, to abate reactions and
interactions, or consult with other physicians.102 The patient also
has a viable negligence claim against the psychiatrist-prescriber
where the diagnosis itself was incorrect.103 But some
commentators assert that the tort system cannot effectively
regulate off-label drug uses, their criticisms focused on a plaintiff’s
burdens in proving medical malpractice liability.104
Both the physician and drug or device manufacturer have
been defendants in lawsuits claiming injury from a prescribed
drug or medical device. In the products-liability actions—
generally arising under theories of strict liability or negligence—
the plaintiff’s claims usually are based on the manufacturer’s
failure to warn of potential risks and dangers.105 However, by
prescribing a medication off-label, a physician unwittingly may
be shielding the manufacturer from liability and exposing herself
to state-level medical malpractice claims if the manufacturer in
fact warned the physician of risks associated with the drug.106

Drugs for Unlabeled Indications, 12 FDA DRUG BULL. 4, 5 (Apr.
1982)).
101. Jadwiga Najib, Drug-Induced Movement Disorders, in DRUG
INJURY: LIABILITY, ANALYSIS AND PREVENTION, 419, 443 (James T.
O’Donnell ed., 3d ed. 2012).
102. Id.
103. Id.
104. Stoffelmayr, supra note 37, at 281 n. 37 (citing William L.
Christopher, Off-Label Drug Prescription: Filling the Regulatory
Vacuum, 48 FOOD & DRUG L. J. 247, 260–62 (1992) and Sydney A.
Shapiro, Limiting Physician Freedom to Prescribe a Drug for Any
Purpose: The Need for FDA Regulation, 73 NW. U. L. REV. 801,
869–72 (1978)).
105. Trasatti & Lanzendorfer, supra note 31, at 8.
106. Id. at 9; see discussion of the Learned Intermediary Doctrine, infra,
Part I.D.3.
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Courts have adopted varying viewpoints regarding a drug
manufacturer’s duties in the context of off-label uses of
prescription drugs,107 and products liability cases in the off-label
drug use arena are most notable for their inconsistency.108 The
competing goals of incentivizing manufacturers to warn of risks
and minimizing penalties for failure to do so109 seem more often
to weigh in favor of protecting manufacturers. Criticisms of such
an approach argue that the drug manufacturer should owe a duty
to warn of any and all known risks associated with an off-label
drug use, whether “demonstrated by the manufacturer’s own
research, the research of others, or physicians’ experiences using
the drug.”110
2. Informed Consent

Most patients fairly assume that the drugs their physician
prescribes are FDA-approved,111 not understanding that once a
drug is approved by FDA, it may be used for any purpose or
population.112 Interestingly, despite the controversial nature of
off-label prescription, little has been said or published addressing
informed consent for off-label use.113 While FDA requires explicit
written consent for drugs being tested in clinical trials, no such
requirement attaches in the context of off-label prescriptions
where, as in any other medical treatments, the doctor believes
that he is using the drug in a manner that serves the patient’s
best interests.114 The doctrine of informed consent imposes no

107. Stoffelmayr, supra note 37, at 276 (footnote omitted).
108. Id. at 275–76 n. 7.
109. Id. at 276.
110. Id.
111. Mithani, supra note 1, at 577 (citing Wilkes & Johns, Informed
Consent and Shared Decision-Making: A Requirement to Disclose
to Patients Off-Label Prescriptions, 5 PLOS MED. e223 (2008)).
112. Id.
113. Id.; see also Berry, supra note 16, at 34 (“The general public is
likely under the impression that if their doctor is prescribing a
medical treatment, it has been tested and approved for that
particular use.”).
114. Am. Acad. of Pediatrics Comm. on Drugs, Uses of Drugs Not
Described in the Package Insert (Off-Label Uses), 110 PEDIATRICS
181, 182 (2002).
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specific duty on the physician to inform the patient that the use
of a drug, including an antipsychotic, is off label.115
Failure to obtain informed consent is a failure to advise a
patient of risks and potential risks associated with a proposed
treatment, which all is material information required for a patient
to make an informed decision about the treatment.116 In a legal
proceeding, the patient-plaintiff often may assert that had he
known of the risks, then he would not have consented to
treatment with the offending drug.117 From a legal perspective, as
the risk of a treatment rises, so too does the duty to warn,
monitor, and consider alternative treatments.118 The physician
would simultaneously best serve the patient’s and his own
interests by focusing on safety and efficacy, and managing risk of
malpractice liability by “following the traditional golden
standards of medicine”: get informed consent, practice evidencebased medicine, integrate specialized medicine, and provide
comprehensive follow-up care.119
Determining what qualifies as “significant or material”
consent depends on the particular patient’s needs, capabilities,
and wishes,120 as well as on the nature of the proposed treatment.
Exceptions to informed consent requirements include patient
incompetence,121 and among the common symptoms in psychiatric
illness are impaired reasoning.122 However, where a psychiatrist is
115. Helm, supra note 90, at 168; see Rebecca Dresser & Joel Frader,
Off-Label Prescribing: A Call for Heightened Professional and
Government Oversight, 37 J.L. MED. & ETHICS 476, 480 (2009)
(“The few courts that have considered the question have concluded
that a product’s regulatory status is not part of the medical
information that physicians must disclose about a proposed offlabel treatment (unless it is administered in the context of
research).”).
116. Barkus & Derian, supra note 20, at 863.
117. Id. at 861.
118. Najib, supra note 101, at 443 (footnote omitted); see also Barkus
& Derian, supra note 20, at 862 (“[A] physician is required to
disclose any significant or material risks associated with the
treatment, as well as any available alternatives.”).
119. Najib, supra note 101, at 443 (footnote omitted).
120. Barkus & Derian, supra note 20, at 862.
121. Id.
122. Thurin et al., supra note 42, at 35.
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contemplating prescription of antipsychotics, off label or not, one
would think that the patient (or the patient’s legal
decisionmaker) must be informed of the risks of drug-induced
movement disorders and other potential adverse effects, along
with any potential benefits of use, before commencing
antipsychotic treatment.123 Too frequently, however, this risk
information is not shared with the patient or surrogate. Often
times, psychiatric patients are persuaded by the “‘insulin for
diabetes’ metaphor,” where the psychiatrist explains that there is
a chemical basis to mental illness and the psychotropic drug will
fix it, just as insulin does for the diabetic.124 The metaphor serves
as “a summation of the risks and benefits,” and once this
summary “is presented to a psychiatric patient, the patient can
be understood to be misinformed about risks and benefits.”125
3. “Learned Intermediary Doctrine” Protects Manufacturers

The learned intermediary doctrine, first officially identified in
a 1966 decision of the Eighth Circuit Court of Appeals,126
recognizes that if a treating physician received adequate notice of
possible risks, the manufacturer has no duty to warn the end
consumer.127 As such, the doctrine often affects the apportionment
of liability between the physician and the pharmaceuticals
manufacturer.128 Using the learned intermediary doctrine as an
affirmative defense, the pharmaceuticals manufacturer can shift
blame for any patient injuries to the prescribing doctor. This is
because liability usually will not extend to the manufacturer
where it could not have foreseen the off-label use or the physician
failed to convey manufacturer-recommended warnings to the
patient.129
123. Najib, supra note 101, at 443.
124. ROBERT WHITAKER & LISA COSGROVE, PSYCHIATRY UNDER
INFLUENCE 157–58 (2015).

THE

125. Id.
126. Sterling Drug Inc. v. Cornish, 370 F.2d 82, 85 (8th Cir. 1966).
127. Barkus & Derian, supra note 20, at 865 (citing Richard B. Goetz
& Karen R. Growden, A Defense of the Learned Intermediary
Doctrine, 63 FOOD & DRUG L. J. 421, 421 (2008)).
128. Helm, supra note 90, at 168 (citing Marcus v. Specific Pharms. Inc.,
77 N.Y.S.2d 508, 509–10 (N.Y. App. Term. 1948)).
129. Id. Note, however, that increases in DTC marketing are chipping
away at protections for manufacturers, as there sometimes is no
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Under the learned intermediary doctrine, pharmaceuticals
manufacturers generally have no duty to warn patients of risks
associated with a drug’s use, only a duty to warn prescribing
physicians.130 Several recent U.S. Circuit Court cases confirm this
line of thought. For example, in Payne v. Novartis
Pharmaceuticals Corp.,131 in addressing the plaintiff’s claims
against a manufacturer of bisphosphonates that allegedly caused
osteonecrosis of the jaw, the court stated that “[a]t base, the
doctrine can shift liability from drug companies to doctors: If the
drug company adequately warned and instructed the doctor but
the doctor did not adequately warn and instruct the patient, the
patient’s quarrel is with the doctor rather than the drug
company.”132
Thus, a patient who suffers a drug injury due to lack of
informed consent has a cause of action against the prescribing
physician for medical malpractice instead of against the drug
manufacturer for products liability.133 Were the manufacturer to
warn the unsophisticated or uneducated patient of the potential
risks, this warning would be insufficient because the patient,
unlike the doctor, is not trained in appraising medical risks.134
This is one reason why the manufacturer’s duty is only to warn
prescribing physicians, who then assume responsibility for
real intermediary. Id. at 169 (“DTC advertising tends to undercut
the rationale behind the doctrine.”). Interestingly, Helm notes that
“the duty for pharmaceutical manufacturers to warn the patient
directly is supported by the Restatement (Third) of Torts:
Products Liability § 6(c)–(d) (1998).” Id.
130. Stoffelmayr, supra note 37, at 284–85 (footnote omitted).
131. Payne v. Norvartis Pharmaceuticals Corp., 767 F.3d 526, 531 (6th
Cir. 2014).
132. See also Mink v. Smith & Nephew, Inc., 860 F.3d 1319, 1329 (11th
Cir. 2017) (holding, under the learned-intermediary doctrine, that
Florida law barred the plaintiff-patient’s negligence claim against
a hip joint replacement system manufacturer based on the theory
that the manufacturer’s training of the physician was inadequate,
and alleging that the manufacturer breached its duty to correctly
train the plaintiff’s physician on how to implant the system; any
duty the manufacturer had in regards to training was owed to the
physician, not the patient).
133. Barkus & Derian, supra note 20, at 865; see also ABOOD &
BRUSHWOOD, supra note 8, at 230.
134. ABOOD & BRUSHWOOD, supra note 8, at 230.
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informing patients of risks of using the drug or device.135 Some
argue that since the physician is in the better position to
understand and weigh the risks and benefits in contemplating the
specific patient’s needs and conditions, the learned intermediary
doctrine is valid.136 Yet another rationale offered to support the
doctrine is that doctors often have close and sometimes personal
connections to patients and are more practically and effectively
able to discuss risks and warnings than could a detached
pharmaceuticals manufacturer.137
Use of the learned intermediary doctrine as a defense has
allowed pharmaceuticals manufacturers to limit or decrease
products-liability claims regarding pharmaceuticals since the 1966
Court of Appeals decision.138 Pharmaceuticals manufacturers
continue to assert this defense, successfully insulating the
companies from liability in negligence and strict liability actions,
including design defect, misbranding, and breach of implied
warranty claims.139
135. Trasatti & Lanzendorfer, supra note 31, at 9 (“For the doctrine to
apply, however, the physician must be aware of the risks associated
with each drug or device. This awareness does not have to come
from the manufacturer. Indeed, even if a manufacturer’s warning is
inadequate, the doctrine will still apply if the physician has been
sufficiently warned from other sources. In essence, the learned
intermediary doctrine encompasses the physician’s entire field of
knowledge.”).
136. Id. at 9 (citing Lee v. Baxter Healthcare Corp., 721 F. Supp. 89, 95
(D. Md. 1989), aff’d, Lee v. Baxter Healthcare Corp., 898 F.2d 146
(4th Cir. 1990)).
137. Barkus & Derian, supra note 20, at 865.
138. Though there are exceptions—for example, cases involving mass
immunization, use of certain contraceptives, and instances where
FDA has mandated that a manufacturer warn the consumerpatient directly. Id.
139. Trasatti & Lanzendorfer, supra note 31, at 8 (citing Fellows v. USV
Pharm. Corp., 502 F. Supp. 297, 299–301 (D. Md. 1980); but see
id. at 11–12 (“Personal injury claims increasingly allege injury from
off-label use of medical products. These claims create a dilemma
for pharmaceutical companies: the learned intermediary doctrine
applies when physicians are aware of the risks associated with drug
or device, but manufacturers are only required to warn physicians
of risks associated with on-label uses and cannot know of all of the
possible off-label uses of a medical product and the risks associated
with those uses. In turn, this dilemma has resulted in substantial
differences among state court decisions regarding a manufacturer’s
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State laws and court decisions on application of the learned
intermediary doctrine vary, with some considering “the totality
of the circumstances, including the manufacturers’ knowledge,
their promotion of the off-label use, and/or the foreseeability of
the use”; some assuming that manufacturers always are dutybound to warn, thus refusing to apply the doctrine where
warnings are absent; and others always applying the doctrine on
the basis that a physician must use her knowledgebase and draw
from her training in determining the best course of treatment for
patients.140 This is troublesome because uniformity is lacking in
state responses to harms arising from the same legal concept (that
is directly tied to federal law on drug safety and efficacy, and
permissible off-label prescription), leaving patients with similar
claims in very different legal positions. As a group widely
prescribed antipsychotics off label, nonpsychotic psychiatric
patients—whether personally aware of it or not—are burdened by
this legal uncertainty.
In the context of psychiatric practice, much in individual
treatment is uncontrolled and unregulated, and the courts do
little-to-nothing to reel in the potential chaos. For example, in
Boehm v. Eli Lilly & Co.,141 the Eastern District of Arkansas
considered the case of a patient-plaintiff who developed tardive
dyskinesia (TD)142 after three years taking the atypical
antipsychotic, Zyprexa, for an approved but nonpsychotic
diagnosis. The drug first was prescribed by a general practitioner,
then later continued by a psychiatrist. The patient-plaintiff sued
the pharmaceuticals manufacturer for failure to warn about the
substantial risks of developing TD, but the district court
dismissed the claim based on the Arkansas learned intermediary

liability for failure to warn claims involving off-label use.”). The
authors further note, however, that “West Virginia’s highest court,
the Supreme Court of Appeals, is the only court to have rejected
the learned intermediary doctrine.” Id. at 11 (citing Johnson &
Johnson Corp. v. Karl, 647 S.E.2d 899, 913–14 (W. Va. 2007)); see
also Barkus & Derian, supra note 20, at 861, 865.
140. See Trasatti & Lanzendorfer, supra note 31, at 13–19.
141. Boehm v. Eli Lily & Co., 747 F.3d 501, 502 (8th Cir. 2014) reh’g
and reh’g en banc denied (Apr. 15, 2014).
142. Tardive dyskinesia is an involuntary movement disorder long
recognized as a side effect of antipsychotic drugs. See discussion of
adverse side effects, infra, Part II.A.2.

260

Health Matrix·Volume 30·2020
The Off-Label Loophole in the Psychopharmacologic Setting

doctrine.143 While the plaintiff argued that he had presented
substantial evidence that Lilly’s warning to physicians as to the
risk of developing TD after long-term use of Zyprexa was
inadequate, the court disagreed, barring recovery against the
manufacturer.144 Ultimately, the court’s reasoning was rational:
Lilly’s package insert warned the prescribing doctors that
though [TD] was an infrequent side effect, the risk that it
would occur and become irreversible . . . was believed to
increase as treatment continued over time and the patient’s
total cumulative dose increased. . . . No studies or other
evidence existed to guide prescribers about deploying the
drug for more than one month. . . . Drs. Miller and
Kaczenski knew all these risks from reading
the Zyprexa package insert and from their experience with
first and second generation anti-psychotic medicines. They
prescribed Zyprexa for Timothy Boehm across many
years because, weighing the risks against the benefits of
treating his bipolar disorder, in their opinion the drug
helped him. These two main prescribers thought Lilly’s
warning adequate. Both are still prescribing Zyprexa to
other patients.145

The plaintiff could have pursued claims against the
prescribing physicians, but with caps in many states on medical
malpractice tort claim awards, his ability to recover non-economic
damages would be quite limited. Among other reasons, if the
physicians were following the standard of care for treating a
bipolar patient, there would be little chance the plaintiff would
prevail.
In 2011, a member of Congress proposed legislation and
admonished that Americans needed protection from drug
manufacturers, and proposed outlawing use of the learned
intermediary doctrine and allowing consumers to recover damages
from pharmaceutical manufacturers directly.146 “Medications are
143. Boehm v. Eli Lilly & Co., No. 4:10-CV-159-DPM, 2012 WL
12848432, at *5 (E.D. Ark. Oct. 4, 2012), aff’d, 747 F.3d 501 (8th
Cir. 2014).
144. Boehm, 747 F.3d at 507–08.
145. Id.
146. 157 CONG. REC. E199 (daily ed. Feb. 10, 2011) (statement of Rep.
Filner).
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meant to heal us,” the congressman stated, “but sometimes,
something goes horribly wrong, and the medicine that was
supposed to make us better, only makes us sicker. When this
happens, Americans should be able to hold the drug
manufacturers responsible.”147 The proposed Bill went nowhere.
Drug manufacturers are in the best position to issue warnings
of risks associated with using their drugs.148 With the ability for
broad monitoring—which is not feasible for the individual
physician treating an individual patient—“drug manufacturers
are, due to their superior ability to warn, the cheapest cost
avoiders.”149 This does not place an undue or unfair burden on
the manufacturer because, if found liable, the company generally
can pursue contribution and indemnity claims against the
physician whose negligence gave rise to the plaintiff’s injuries.150
Still, there have been instances where courts have found that a
physician’s negligence—especially if unforeseeable—may absolve
a manufacture of “all liability for failure to warn of the risks
associated with the use of its drug.”151 For example, in Ferrara v.
Berlex Laboratories, Inc.,152 a products liability action against
manufacturers of a prescription antidepressant (Nardil) and an
over-the-counter decongestant (Deconamine), for failure to warn
patients of the products’ dangerous synergistic side effects, the
court held that under Pennsylvania law the learned intermediary
doctrine precluded manufacturer liability.
Several jurisdictions impose limits on recovering noneconomic losses against health care providers, but these statutory
147. Id.
148. Stoffelmayr, supra note 37, at 285.
149. Stoffelmayr argues, “[i]mposing a duty on manufacturers to warn
of the risks of off label drug uses does not, as might be feared, turn
manufacturers into insurers for physicians who carelessly prescribe
dangerous off-label treatments or who negligently misprescribe
drugs and later characterize their mistakes as off-label treatments.
Injured patients can still bring medical malpractice suits against
negligent physicians.” Id. at 289.
150. Id. (citing Charles F. Preuss, Measures of Liability, in PRODUCTS
LIABILITY: DRUG CASES 303, 322–30 (Donald E. Vinson &
Alexander H. Slaughter eds., 1988)).
151. Id. at 289 (emphasis added).
152. Ferrara v. Berlex Lab., Inc., 732 F. Supp. 552, 553 (E.D. Pa. 1990),
aff’d, 914 F.2d 242 (3d Cir. 1990).
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limits do not apply to pharmaceuticals manufacturers; thus a
physician’s liability for non-economic damages might be capped
at $250,000, but the drug manufacturer’s liability for those
damages could be exponentially higher.153 But not if that
manufacturer is shielded from liability altogether.154
The learned intermediary doctrine protects pharmaceuticals
manufacturers from liability, shifting the “blame” or
responsibility to the doctor. It may seem at first glance that
physicians are assuming great professional and financial risks by
prescribing medications off-label, because they will be “left
holding the bag.” However, physicians have their own legally
recognized means for self-protection, most significantly the
accepted “standard of care.”
4. “Standard of Care” Protects Physicians

Courts generally consider off-label prescribing to be
legitimate if it meets the standard of reasonable care.155 Thus,
liability usually will not extend to the physician where the offlabel use is the accepted standard of care in the physician
community.156 In any medical malpractice action, the patientplaintiff must establish that the physician failed to adhere to the
accepted standard of care.157 In order for a medical malpractice
claim to succeed on these grounds, the plaintiff must demonstrate
the existence of a direct physician-patient relationship and that
the physician significantly departed from the standard of care of
a reasonable physician.158 While state laws vary in their exact
determinations of accepted standards of care, generally the bar is
153. Barkus & Derian, supra note 20, at 866 (citing CAL. CIV. CODE
§ 3333.2 (1872)).
154. In subsequent cases, major precedential developments effectively
have shielded generic pharmaceuticals manufacturers from all
liability for failure to warn in labeling. See, e.g., Pliva, Inc. v.
Mensing, 564 U.S. 604 (2011); Mutual Pharmaceutical Co. v.
Bartlett, 570 U.S. 472 (2013). These developments are beyond the
scope of this Article.
155. Helm, supra note 90, at 171; see also Klein v. Biscup, 673 N.E.2d
225, 231 (Ohio App. 8 Dist. 1996).
156. Helm, supra note 90, at 168.
157. Mark Herrmann & Pearson Bownas, Keeping the Label Out of the
Case, 103 NW. L. REV. COLLOQUY 477, 480 (2009).
158. Helm, supra note 90, at 170.
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set quite low, looking at what would be expected of the minimally
competent physician.
In establishing the standard of care in medical malpractice
actions against physicians for off-label use, peer-reviewed medical
journals, introduced by expert testimony, “are generally
considered the only reliable source of sound scientific and medical
opinion.”159 Usually, this expert testimony is required to establish
the medical community’s applicable standard of care and to allow
a jury to ascertain whether the off-label use and warnings
provided to the patient conformed to that standard.160
Some scholars argue that FDA-approved labeling should not
serve as evidence pertaining to the standard of care in litigation
surrounding an off-label prescription gone wrong.161 Ironically, it
is the very off-label use at issue that, if widespread, becomes the
standard of care: the standard of care is the off-label use.162 If
enough psychiatrists are prescribing antipsychotics to
nonpsychotic patients, this becomes—and actually has become—
the standard of care.163 In treating individual patients, but in
concert, psychiatrists have established this new standard of care,
thereby insulating themselves from malpractice liability in courts
of law.164 It follows that the more widespread a drug’s off-label
use—whether based on science, anecdote or myth—the more
impervious to liability is the prescribing physician.

159. Id.; Cf. Mollie E. O’Brien, What Counts as Expert Medical
Testimony?, 6 VIRTUAL MENTOR 554, 555 (2004).
160. Barkus & Derian, supra note 20, at 863.
161. Herrmann & Bownas, supra note 157, at 480.
162. Id. at 486.
163. See Alex R. Thiersch, Legal Issues: Off-Label Uses; Legal, Ethical
and Informed Consent Considerations When Using Products OffLabel, MEDESTHETICS MAG, https://www.medestheticsmag.com/
legal-issues-label-uses
[https://perma.cc/W2XA-Y67A]
(last
visited Dec. 8, 2018) (recommending that providers not put
themselves in a situation where a medical board views their
prescribed treatment as too experimental).
164. One might also consider the extension of this reasoning to informed
consent. If failure to obtain informed consent has become the
customary practice, is the physician’s failure to obtain the patient’s
consent the new, accepted standard of care?
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II. Antipsychotics: Pushing the Limits
Antipsychotics serve a legitimate purpose in treating
psychoses associated with mental illness after the particular drug
has been scientifically shown to be safe and effective for that
particular illness and study population. For the patient suffering
from schizophrenia, antipsychotics can be lifechanging, for the
better. For psychiatric patients not suffering from psychosis,
antipsychotics can make their lives worse.
A. History

Psychosis is marked by hallucinations, delusions, and severely
disordered thought, often accompanied by extreme agitation and
sleep disruption.165 Symptoms of hallucination include false
perceptions (for example, hearing voices that are not there), and
delusions, which are “false beliefs that do not yield to a rational
argument.”166 With severe thought disorder there is a breakdown
in logical connections between successive thoughts.167 Psychosis is
not limited to the experience of patients suffering from
schizophrenia, but also may be a state present in illnesses such as
bi-polar disorder and severe major depressive disorder.
Antipsychotics were developed in the early 1950s to treat
psychoses.168 For patients experiencing psychotic “breaks with
reality,” particularly those associated with schizophrenia,169
antipsychotics provide “a crucial and potentially life-saving
treatment.”170 Reducing dopamine activity within the brain is a

165. Mary C. McCarron, The Right to Refuse Antipsychotic Drugs:
Safeguarding the Mentally Incompetent Patient’s Right to
Procedural Due Process, 73 MARQ. L. REV. 477, 481 n. 24 (1990).
166. Id.
167. Id.
168. Id. at 477 (citing The Forcible Medication of Involuntarily
Committed Mental Patients with Antipsychotic Drugs, 15 GA. L.
REV. 739 (1981) (citing Davis, Antipsychotic Drugs, in FREEMAN
H. KAPLAN & B. SADOCK, COMPREHENSIVE TEXTBOOK OF
PSYCHIATRY (2d ed. 1975)).
169. Id. at 480–81.
170. Brendan L. Smith, Inappropriate Prescribing: Research Shows
That All Too Often, Americans Are Taking Medications That May
Not Work or May Be Inappropriate for Their Mental Health
Problems, 43 MONITOR ON PSYCHOL. 36 (June 2012).
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common action of all antipsychotics.171 More specifically, a
primary function of antipsychotics is accomplished through
dopamine receptor-blocking agents—also known as neuroleptics
and/or
major
tranquilizers—that
block
dopamine
neurotransmission in the brain.172 Earlier antipsychotics were
problematic because they were difficult to tolerate due to adverse
side effects, particularly extrapyramidal side effects.173 In the
1990s, pharmaceuticals manufacturers introduced a new wave of
antipsychotics, interchangeably referred to as second generation
antipsychotics (SGAs) and atypical antipsychotics.174 In addition
to reducing dopamine activity, SGAs work to block serotonin
receptors.175
In the 1990s, major pharmaceuticals companies rolled out
SGAs, such as Risperdal, Seroquel and Zyprexa, touting these
new drugs as superior to first generation antipsychotics.176 SGAs
supposedly were better tolerated by the patient suffering from
schizophrenia, with fewer adverse side effects.177 But SGAs have
not fully lived up to this promise, with virtually all SGAs having
a propensity to cause certain degrees of adverse side effects.178 In
fact, widespread use of SGAs followed at least one manufacturer’s
now-documented suppression of unfavorable studies, and the
manipulation and reporting of findings and results through
academic psychiatrists with “apparent scientific legitimacy.”179
Some experts now assert that while less cost effective than firstgeneration antipsychotics, SGAs are “no more efficacious, do not

171. DAVID HEALY, PSYCHIATRIC DRUGS EXPLAINED 28 (5th ed. 2009)
[hereinafter HEALY—PSYCHIATRIC DRUGS].
172. Najib, supra note 101, at 420.
173. Divac et al., supra note 5, at 1.
174. Id.
175. H. Meltzer & B. Massey, The Role of Serotonin Receptors in the
Action of Atypical Antipsychotic Drugs, 11 CURRENT OPINION
PHARMACOLOGY 59, 60 (2011).
176. See WHITAKER & COSGROVE, supra note 124, at 77–85.
177. Divac et al., supra note 5, at 2.
178. Id.
179. WHITAKER & COSGROVE, supra note 124, at 85.
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improve specific symptoms, [and] have no clearly different side
effect profiles” than their predecessors.180
Antipsychotic drugs alleviate the major disruptive
manifestations of psychosis, but their side effects are sometimes
equally disruptive.181 While they are designed for patients
suffering from psychoses, within the psychiatric profession, their
prescription—even to the patient suffering from psychosis—is
controversial due to the long-term risks associated with their
use.182 Yet, SGA prescription in the U.S. almost tripled between
1995 and 2008, expanding to over 16 million prescriptions for
aripiprazole (Abilify), clozapine (Clozaril) and quetiapine
(Seroquel).183 Disconcertingly, according to a study by Stanford
University and the University of Chicago surveying over 1,700
physicians, fifty-percent of those prescriptions in 2008 were for
uses not supported by scientific evidence.184 If such a large number
of antipsychotics prescriptions are written for indications and
populations never studied, then what valid purposes are they
serving? Closer examination of these off-label uses shows that
180. Id. (quoting Peter Tyrer & Tim Kendall, The Spurious Advance of
Antipsychotic Drug Therapy, 373 LANCET 4, 4–5 (2009) for the
proposition that “[t]he spurious invention of the atypicals can now
be regarded as invention only, cleverly manipulated by the drug
industry for marketing purposes and only now being exposed. But
how is it that for nearly two decades we have been beguiled into
thinking they were superior?”).
181. McCarron, supra note 165, at 483 n. 36 (footnotes omitted). One
recipient of a psychotropic injection depicts his experience this way:
There is no other feeling like it. Nothing to relate it to, no
experience anyone would normally go through in their life. It affects
you mentally and physically and you feel suicidal. The physical
effects are so bad you can’t stand it. . . . You get so tired (as if
you’ve been up three days in a row) you lie down. But you can’t
stay down for more than three or four minutes because your knees
begin to ache, an itching type ache. . . . Your thoughts are broken,
incoherent; you can’t hold a train of thought for even a minute.
You’re talking about one subject and suddenly you’re talking about
another. . . . Your mind is like a slot machine, every wheel spinning
a different thought.
Opton, Psychiatric Violence Against Prisoners: When Therapy is
Punishment, 45 MISS. L. J. 605, 641 (1974).
182. McCarron, supra note 165, at 477 (footnote omitted).
183. Smith, supra note .
184. Id.
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claims of legitimate clinical treatment purposes are often suspect,
and sometimes clearly spurious.
1.

Sedation, Control, and Punishment, Not Treatment

An antipsychotic’s immediate effect on patients is sedative.185
By influencing chemical transmissions in the brain, antipsychotics
sedate the patient suffering from schizophrenia “and suppress
psychotic symptoms such as delusions, hallucinations, and other
disorders.”186 Antipsychotic drugs do not cure the patient of
mental illness, but may limit some of the more burdensome
symptoms.187 Some authorities maintain that with proper drug
maintenance and therapy, relapse can be prevented for a
substantial number of patients who suffer from schizophrenia.188
However, given the myriad severe side effects, many psychiatric
patients suffering from psychosis justly wish to refuse
antipsychotics and instead elect to suffer through psychotic
episodes.189
Extremely problematic are uses of antipsychotic drugs for
non-treatment purposes, such as convenience of nursing home
staff or to discipline or control nonpsychotic persons in custody
or confinement.190 Extensive exposition on these questionable uses
is beyond the scope of this Article, but it is noteworthy here that
in many instances, clinical treatment of an individual’s mental
illness is not the primary purpose of prescribing antipsychotics.191
185. McCarron, supra note 165, at 482 n. 33 (citing R. Byck, Drugs and
the Treatment of Psychiatric Disorders, in THE PHARMACOLOGICAL
BASIS OF THERAPEUTICS 158 (L. Goodman & A. Gilman eds.,
1975)).
186. Id. at 481; See also Vicki Anderson, Right to Refuse Antipsychotic
Medication: A Proposal for Legislative Consideration, 17 IND. L.
REV. 1035, 1038–39 (1984).
187. McCarron, supra note 165, at 481 (citing E. Symonds, Mental
Patient’s Rights to Refuse Drugs: Involuntary Medication as Cruel
and Unusual Punishment, 7 HASTINGS CONST. L. Q. 701, 704
(1980)).
188. Id. at 705 n. 22.
189. Id.
190. Id. at 484 (footnote omitted); see Part II.B, infra.
191. See, e.g., US: Nursing Homes Misuse Drugs to Control Residents,
HUM. RIGHTS WATCH (Feb. 5, 2018, 3:01 AM), https://www.hrw
.org/news/2018/02/05/us-nursing-homes-misuse-drugs-controlresidents [https://perma.cc/BCV5-GAF9].
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In prison settings, the reason of “dangerousness to others” may
permissibly be used to justify forced administration of
antipsychotics, despite the availability of less intrusive or harmful
measures.192
2.

Other Side Effects

While antipsychotics have some positive effects for patients—
like the ability of a patient suffering from schizophrenia to
function at home and even in the workforce—the increased
freedom often comes with a high price.193 Some negative side
effects will cease upon discontinuation of medication, but others
are “serious, long-lasting and potentially more disruptive than the
illness itself.”194 Studies have shown that when antipsychotics are
used to treat patients suffering from schizophrenia, the presence
of extrapyramidal side effects go undetected and, though
recommended by the American Psychiatric Association (APA),
documentation of significant adverse effects is not routine.195
Extrapyramidal side effects include akathesia/Parkinsonian
syndrome, dystonia and akinesia.196 Akathesia/Parkinsonian
syndrome often is thought of as “the jitters,” and is a
nonpermanent condition where the patient feels restless, cannot
remain still and feels compelled to move and pace.197 Interestingly,
research on akathesia shows that this very side effect, caused by
the antipsychotic, frequently is misdiagnosed as a symptom of
psychosis.198 Often, the result of this faulty inference is physicianordered dosage increases of the culpable antipsychotic

192. See Washington v. Harper, 494 U.S. 210, 217 (1990).
193. McCarron, supra note 165, at 482.
194. Id. at n. 29 (citing Steven Shobat, Pathway Through the
Psychotropic Jungle: The Right to Refuse Psychotropic Drugs in
Illinois, 18 J. MARSHALL L. REV. 407, 411 (1985)).
195. Najib, supra note 101, at 442–43.
196. McCarron, supra note 165, at 482 (footnotes omitted).
197. Id. at n. 30 (quoting E. MAGGIO, THE PSYCHIATRY-LAW DILEMMA
225 (1981)).
198. Id.; see also HEALY—PSYCHIATRIC DRUGS, supra note 171, at 31
(stating akathisia is possibly the most serious side effect of
antipsychotics).
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medication.199 Dystonia involves muscular spasms, primarily in
the head and neck, often combined with odd facial grimaces and
tongue spasms.200 Akinesia has the effect of restricting a patient’s
movements, even making the patient feel as though in a
straitjacket.201 Just one dose has the power to make anyone
appear to be suffering from schizophrenia,202 because if the
akinesiac effect is severe, then it can result in a patient “sitting
motionless in one place, almost like a zombie.”203 All three—
akathesia/Parkinsonian syndrome, dystonia and akinesia—can be
minimized by lowering the dosage, discontinuation, or by use of
anti-Parkinsonian drugs.204
TD is the most devastating side effect, largely because
oftentimes it is irreversible, even upon discontinuation of the
antipsychotic.205 TD includes “involuntary, rhythmic movements
of the face, mouth, tongue, and jaw.”206 While SGAs have a lower
incidence of TD than first generation antipsychotics,207 the risk of
developing TD with either type of antipsychotic is believed to
increase as a patient’s lifetime dose increases.208 Serious side
effects more often associated with SGAs include hormonal
changes (i.e. an increase in the level of prolactin through D2
receptor binding),209 in addition to metabolism changes, major
199. McCarron, supra note 165, at 482 (citing Symonds, supra note 187,
at 707–08).
200. Id. at n. 31 (quoting Symonds, supra note 187, at 707 n. 37).
201. HEALY—PSYCHIATRIC DRUGS, supra note 171, at 29.
202. Id.
203. Id.
204. McCarron, supra note 165, at 482 (footnotes omitted).
205. Id. at 482.
206. Id. (footnote omitted).
207. Maren Carbon et al., Tardive Dyskinesia Risk with First- and
Second-Generation Antipsychotics in Comparative Randomized
Controlled Trials: A Meta-Analysis, 17 WORLD PSYCHIATRY 330,
336 (2018).
208. Id. at 332.
209. Id. An increased prolactin level can cause breasts to develop in boys
and men (with lactation) and lactation to begin in non-nursing
women. HEALY—PSYCHIATRIC DRUGS, supra note 171, at 34–5; see
also Steven Brill, America’s Most Admired Lawbreaker,
HUFFINGTON POST, http://highline.huffingtonpost.com/miracle
industry/americas-most-admired-lawbreaker/ [https://perma.cc/
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weight gain,210 and an increased risk of irreversible diabetes.211
These metabolic changes are known as “metabolic syndrome.”
Among other side effects are demotivation, sexual side effects,
skin rashes, dry mouth and compulsive drinking, aggression and
impatience, neuroleptic malignant syndrome, cardiovascular
conditions, epilepsy, suicide and severe withdrawal effects.212
Though absurd and unexpected in this age of evidence-based
medicine, there are instances where “evidence” has been created
in order to defend against and disprove adverse events appearing
in clinical-trial data.213 For example, following concerns in the
mid-1990s that Zyprexa, an antipsychotic, might cause diabetes,
Eli Lilly dug through history to revive an association between
psychosis and diabetes “documented” by Henry Maudsley in
1879.214 The company then authored or sponsored articles that
liberally used this anecdotal “evidence” as support for a causal
connection between schizophrenia and diabetes—asserting that it
was the schizophrenia “after all, and not Zyprexa, that was
causing the problem.”215 There were no published objections either
in the U.S. or Europe from members of the psychiatric
profession.216 In a 2004 study examining 396 patients suffering
D2EB-MFFB] (last visited Dec. 7, 2018) (documenting a classaction lawsuit against Johnson & Johnson for adverse side effects
from Risperdal).
210. David Arterburn et al., Antipsychotic Medications and Extreme
Weight Gain in Two Health Systems, 10 OBESITY RES. & CLINICAL
PRAC. 408, 409 (2016).
211. JULIE HOLLAND, MOODY BITCHES 315–16 (2015); See also Najib,
supra note 101, at 434 n. 88.
212. HEALY—PSYCHIATRIC DRUGS, supra note 171, at 33–41. As is the
case with antidepressants, withdrawal effects from antipsychotics
can be misinterpreted by both the psychiatrist and patient as
evidence that the medication is needed, and can bolster the
sometimes-inaccurate assumption that the treatment and not
“placebo factors have brought about a clinical response.” Id. at 59.
In such instances, where an antipsychotic is being used off-label
because there have been no clinical studies to either support or
refute assumptions regarding efficacy, “science” is no more than a
guess.
213. DAVID HEALY, PHARMAGEDDON 218 (2012).
214. Id.
215. Id.
216. Id.
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from psychosis, not a single one had type-2 diabetes.217 Once
treated with antipsychotics, these patients developed diabetes at
twice the normal rate.218 Yet, most physicians have been swayed
by the anecdote repeatedly “reported” by pharmaceuticals
manufacturers.219
Psychiatric patients suffering from schizophrenia or other
psychosis-inducing illnesses may feel that treatment with
antipsychotics is quite beneficial. While this is not always the
case, these individuals and their physicians may have assessed
that the risks of adverse side effects are justified by the benefits
of being able to live without psychosis. In instances where
antipsychotics are used to sedate and control people in
institutional settings, such as prisons and nursing homes, it is
doubtful that a meaningful balancing of risks versus benefits is
even contemplated: if it is, risks to the ward or patient seem to
be given less weight than the benefit of alleviating burdens on
institution staff-members. For any person not suffering from
psychosis, justification for using antipsychotics in the risk/benefit
analysis is quite thin.
B. Prevalence of Antipsychotic Use in Nonpsychotic Patient
Population

Diagnosis in the realm of psychiatry is inexact and imperfect,
thus psychiatrists often face challenges in determining which
medications will be appropriate for a particular patient. In
instances where definitive diagnosis is difficult, it is not
uncommon that a psychiatrist attempting to achieve the best
outcome might prescribe multiple medications, some of them off
label.220 Confronted with confusing or contradictory symptoms,
217. Id. (citing Joanna Le Noury et al., The Incidence and Prevalence
of Diabetes in Patients with Serious Mental Illness in North West
Wales: Two Cohorts 1875–1924 and 1994–2006 Compared, 8 BMC
PSYCHIATRY 67 (2004).).
218. Id.
219. Id.
220. Andrew McKean & Erik Monasterio, Off-Label Use of Atypical
Antipsychotics Cause for Concern?, 26 CNS DRUGS 383, 384,
(2012) (citing D.C. Radley et al., Off-label Prescribing Among
Office-Based Physicians, 166 ARCH. INTERN. MED. 1021–26 (2006);
D. Leslie et al., Off Label Use of Antipsychotic Medications in the
Department of Veterans Affairs Health Care System, 60(9)
PSYCHIATRIC SERVS. 1175–81 (2009); Haw C & Stubbs J., A Survey
of the Off-Label-Use of Mood Stabilizers in a Large Psychiatric
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“physicians can pull from a hat some case from the past and make
their recommendation, often leading to the patient’s recovery.”221
But mechanisms by which psychiatrists gather information from
and about patients are uncertain, and (even if obtained from the
patient directly) the information may be unreliable and merely
anecdotal.222 Misdiagnosis in psychiatry has been estimated to be
as high as fifty percent, and nonpsychotic patients who may be
perceived as exhibiting some symptoms of the disease, or none at
all, may be prescribed antipsychotics inappropriately.223
1.

Just a Little Bit Can’t Hurt, Can it?

Prescription of antipsychotics “should be restricted to only
those patients for whom no alternative treatment is available.”224
Increasingly, however, SGAs are prescribed as mood stabilizers.
For example, FDA has granted approval for treating bipolar
disorder with the following medications: Risperdal, Abilify and
Seroquel.225 While some of the newer indications are approved by
FDA, most are not.
U.S. office-based psychiatrists increasingly are prescribing
two or more psychotropic medications concurrently; the
combination of antidepressants and antipsychotics is prevalent,
and many times the antipsychotics are prescribed off label.226 This
Hospital, 19 J. PSYCHOPHARMACOLOGY 402–7 (2005); K. MartinLatry et al., A One-Day Survey of Characteristics of Off-Label
Hospital
Prescription
of
Psychotropic
Drugs,
40(3)
PHARMACOPSYCHIATRY 116–20 (2007)).
221. DAVID J. ROTHMAN, STRANGERS AT THE BEDSIDE: A HISTORY OF
HOW LAW AND BIOETHICS TRANSFORMED MEDICAL DECISION
MAKING 7 (2003).
222. Id.
223. McCarron, supra note 165, at 483 (footnotes omitted).
224. Najib, supra note 101, at 443.
225. HOLLAND, supra note 211, at 315.
226. Lone Baandrup & Marie Kruse, Incident Users of Antipsychotics:
Who Are They and How Do They Fare?, 51 SOC. PSYCHIATRY&
PSYCHIATRIC EPIDEMIOLOGY 505, 506, 511 (2016) (citing R.
Mojtabai & M. Olfson, National Trends in Psychotropic
Medication Polypharmacy in Office-Based Psychiatry, 67 ARCH.
GEN. PSYCHIATRY 26 (2010)). In addition to a lack of evidence of
efficacy, the potential for drug-drug interactions and increased side
effects is often a real but unnecessary burden on patients. Id. at
511.
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is often referred to as adjunctive therapy.227 A U.S. national
survey concluded that efficacy was not proved for these off-label
uses and risk-benefit ratios and outcomes were uncertain.228
Efforts are needed to place limits on off-label uses of
antipsychotics, reserving these uses for very specific and otherwise
treatment-resistant conditions.
While in some instances psychiatrists are prescribing lower
doses for their nonpsychotic patients than they would for treating
FDA-approved indications (for example, schizophrenia),229 lower
doses of SGAs are not without risk. Still, these lower doses are
commonly prescribed off label to “treat” anxiety, agitation, and
insomnia, and there may be an assumption that the use of these
drugs in lower doses will significantly mitigate risks of metabolic
adverse effects.230 This assumption is faulty. Chronic, low-dose use
of adjunctive antipsychotic medication in treating depression has
been found to result in increased blood lipids, triglycerides and
glucose, with attendant weight gain and increased risk of Type II
diabetes.231 For example, one study looked at patients between
ages nineteen and sixty-five who were prescribed low-dose
quetiapine (mean daily dose of 120 mg at the end of the study)
in treating insomnia: over an 11-month period there were
significant changes in weight (mean increase of 4.9 pounds) and
body mass index (mean increase of 0.8).232 Clearly, off-label use
227. Id. at 506.
228. Id. at 511.
229. Antipsychotic Drugs a Last Resort for These 5 Conditions: Safety
Issues Are a Concern When Used Off-Label to Treat Anxiety,
ADHD, Depression, Insomnia, and PTSD, Our Analysis Finds,
CONSUMER REPORTS (Dec. 2013), https://www.consumer
reports.org/cro/2013/12/treating-anxiety-adhd-depressioninsomnia-and-ptsd-with-newer-antipsychotics/index.htm [https://
perma.cc/R92Y-AMGQ] [hereinafter Antipsychotic Drugs a Last
Resort].
230. McKean & Monasterio, supra note 220, at 387 (citing M. Cates et
al., Metabolic Consequences of Using Low Dose Quetiapine for
Insomnia in Psychiatric Patients, 45 CMTY. MENTAL HEALTH J.
25M (2009)).
231. Ping Wang, Use of Antipsychotics in the Treatment of Depressive
Disorders, 25 SHANGHAI ARCHIVES OF PSYCHIATRY 134, 138 (2013).
232. McKean & Monasterio, supra note 220, at 387 (citing M. Cates et
al., Metabolic Consequences of Using Low Dose Quetiapine for
Insomnia in Psychiatric Patients, 45 CMTY. MENTAL HEALTH J.
25M (2009)); See also Holly V. Coe & Irene S. Hong, Safety of Low
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of antipsychotics has potential to harm, but because these uses
are not universally monitored or regulated, concrete information
about side effects in the nonpsychotic population is not readily
available.233
2.

Vulnerable Populations

Particularly worrisome is the off-label prescription of
antipsychotic drugs to members of vulnerable populations.234
Most commonly, this is a situation in which there is no psychosis
but perhaps a desire by psychiatrists, caretakers and society to
control, keep still or quiet the patient. One might expect that the
U.S. Department of Health and Human Services (HHS) would set
an example of proper standards for addressing potential
vulnerability in the psychiatric community through the
department’s regulation of human subjects research with this
population. However, this is not the case.235 HHS, and FDA for
that matter, have no special regulations governing research in the
psychiatric patient population.236 Regarding criteria for IRB

Doses of Quetiapine When Used for Insomnia, 46 THE ANNALS OF
PHARMACOTHERAPY 718, 719 (2012).
233. McKean & Monasterio, supra note 220, at 386.
234. McCarron, supra note 165, at 484.
235. With recent changes to the Common Rule, 83 Fed. Reg. 28518,
28518 (June 19, 2018) (to be codified at 45 C.F.R. § 46), there is
no longer reference to “mentally disabled” subjects. Now, “impaired
decision-making capacity” has replaced “mentally disabled” as a
new but likewise vague concept, and IRBs are tasked with
delineating this concept on a protocol-by-protocol basis. See Elisa
A. Hurley, From the Director: “Vulnerability” in the Revised
Common Rule, AMP&RSAND (Sept. 12, 2017), https://blog.
primr.org/vulnerability-revised-common-rule [https://perma.cc/
6VXZ-CC74]. The revised Common Rule refers to impaired
decision-making capacity in the context of subjects who are
vulnerable to coercion or undue influence. 45 C.F.R. § 46.111(b)
(2019); As with the original Common Rule (45 C.F.R. pt. 46C,
§ 46.111(a)(3)), the definition of vulnerability is difficult to pin
down. For years, scholars have attempted to forge meaning where
little guidance has been provided. See, e.g., David Wendler, A
Pragmatic Analysis of Vulnerability in Research, 31 BIOETHICS 515,
520 (2017).
236. Philip T. Yanos et al., Research Risk for Persons with Psychiatric
Disorders: A Decisional Framework to Meet the Ethical Challenge,
60 PSYCHIATRIC SERVS. 374, 376 (2009).
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approval in the context of clinical drug research, FDA regulations
state:
(b) When some or all of the subjects, such as children,
prisoners, pregnant women, handicapped, or mentally
disabled persons, or economically or educationally
disadvantaged persons, are likely to be vulnerable to
coercion or undue influence additional safeguards have
been included in the study to protect the rights and welfare
of these subjects.237

Our federal research regulations provide no concrete
instructions on how to protect mentally disabled or mentally ill
individuals in research, nor is there any department or agency
guidance regarding how to limit the risks to which these subjects
may be exposed in clinical research.238 The term “mentally
disabled persons” is not defined and could result in various
interpretations. It might mean only instances involving
permanent impairment of decision-making ability, for example,
dementia or brain injury; or, it might also include other instances
that involve temporary impairment, such as an episode of maniainduced psychosis.239 Physicians, researchers and IRB members
need more consistency and clarity in this area. This lack of clarity
in the research setting is reflective of the wide deference that U.S.
law has allowed psychiatrists in determinations relating to
treatment of mentally ill patients.240 It is not a stretch to conceive
237. Note that unlike the revised Common Rule, FDA’s regulation
retains its reference to “mentally disabled persons.” 21 C.F.R.
§ 56.111(b) (2019) (emphasis added).
238. Resnik points to the diversity within the mentally disabled and
mentally ill populations that makes it not necessarily appropriate
to put them in categories: “[S]ome mentally ill or disabled adults
may have good decision-making abilities, while others may not.
Also, some may be able to make decisions under certain conditions
. . . but not [under] others.” DAVID B. RESNIK, THE ETHICS OF
RESEARCH WITH HUMAN SUBJECTS, 218, 227 (2018).
239. See Lindy Marie Fields & James Douglas Calvert, Informed
Consent Procedures with Cognitively Impaired Patients: A Review
of Ethics and Best Practices, 69 PSYCHIATRY & CLINICAL
NEUROSCI. 462, 463–64 (2015).
240. See, e.g., Buck v. Bell, 274 U.S. 200, 200 (1927) (supporting a
Virginia eugenics law, allowing sterilization of people deemed by
physicians to be “mentally defective” “imbeciles.”); see also
Washington v. Harper, 494 U.S. 210, 222 n. 8 (1990) (involving
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of the two disciplines—psychiatric clinical research and
psychiatric clinical practice—as being inextricably intertwined in
the eyes of the law.
In the field of bioethics, there are various types of
vulnerability that are considered to affect a patient’s decision
making. The most relevant in the context of the psychiatristpatient relationship may be deferential vulnerability, cognitive
vulnerability, economic vulnerability, and social vulnerability.241
With deferential vulnerability “the subordination is affected not
by formal hierarchies . . . but instead by informal ones [that may]
be socially constructed,” for example, those related to “gender,
race, or class inequalities,” or “inequalities of power and
knowledge of the kind that occur in doctor-patient
relationships.”242 Deferential vulnerability may often be subtle,243
but is likely present in most psychiatrist-patient relationships.
With cognitive vulnerability, a patient may lack the ability to
understand, for a variety of reasons, the risks of using a drug off
label. A patient may lack sophisticated education and resources
for learning due to economic disadvantages. With social
vulnerability, a patient might possess the “cognitive capacity to
consent,” yet be part of a group perceived by society through the
lens of stereotypes that deflate the value of these individuals, their
interests, welfare and contributions to society.244 Psychiatrists are
not immune to viewing patients through the lens of the
stereotype.
FDA vaguely affords protections for subjects suffering from
mental illness by instructing IRBs to assure adequate safeguards
for the undefined category of “mentally disabled” subjects who
forced antipsychotic medication of incarcerated inmates) (“[W]e
will not assume that physicians will prescribe [antipsychotics] for
reasons unrelated to the medical needs of the patients; indeed, the
ethics of the medical profession are to the contrary. This
consideration supports our interpretation of the State’s Policy as
ensuring that antipsychotic medications will be administered only
in those cases where appropriate by medical standards.”) (citations
omitted).
241. COLEMAN ET AL., supra note 10, at 141–44 (citing ETHICAL AND
POLICY ISSUES IN RESEARCH INVOLVING HUMAN PARTICIPANTS,
NAT’L BIO. ADVISORY COMM’N 85–92 (2001)).
242. Id. at 143 (emphasis in original).
243. Id.
244. Id. at 144.
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are likely to be vulnerable to coercion or undue influence.245
However, federal law leaves the potentially vulnerable psychiatric
patient open to possible exploitation—intentional or not—by
physicians who in clinical practice prescribe antipsychotic drugs
never studied for their particular disease or population.246
3.

Children, Especially Foster Children

Among the existing antipsychotics, risperidone (the generic
for Risperdal) is the drug used most frequently in the childpatient population.247 There has been little official research on the
use of antipsychotic drugs in the child-patient population,
particularly off-label uses.248 The consequence of this widespread
off-label use is that many children are, in effect, enrolled “in a

245. 21 C.F.R. § 56.111(a)(3) (2019).
246. Note that the Common Rule provides protections to everyone else,
provided that the clinical study is connected to federal funding.
While not applicable in the FDA setting, the revised Common Rule
no longer aligns with FDA’s regulation. See COLEMAN ET AL., supra
note 10, at 175–76 (“There are three ways in which a study might
be subject to the federal regulations governing human subject
protection: (1) the study is conducted or funded by the federal
government; (2) the study is conducted at an institution that has
agreed, in the assurance it entered into with the federal
government, to apply the Common Rule to all research taking place
at that institution; or (3) the study concerns something that brings
it within the jurisdiction of the FDA.”). From the perspective of
those who favor regulation, a compelling argument could be
made—and perhaps has been made—regarding the chasm in
protections for subjects in privately funded research that is neither
drug related nor government funded, and the urgent need for
protective action in this area. This inquiry is beyond the scope of
the Article.
247. JASLEEN SALWAN ET AL., APPLICATION FOR INCLUSION TO THE 19TH
EXPERT COMMITTEE ON THE SELECTION AND USE OF ESSENTIAL
MEDICINES: RISPERIDONE, WORLD HEALTH ORG. (Jan. 6, 2013),
available
at
https://www.who.int/selection_medicines/
committees/expert/19/applications/Risperidone_24_A_Ad_Fina
l.pdf [https://perma.cc/LV2X-DVKK].
248. Are Too Many Kids Taking Antipsychotic Drugs? Use Is Climbing
Despite Questions About How Safe the Drugs Are and How Well
They Work, CONSUMER REPS. (Dec. 2013), https://www.consumer
reports.org/cro/2013/12/are-too-many-kids-taking-antipsychoticdrugs/index.htm [https://perma.cc/2SPL-PQ6X] [hereinafter Too
Many Kids].
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sort of large, poorly controlled experiment.”249 Truly evidencebased standards of care are required if there is any chance of
understanding how best—if at all—to use psychotropic
medications off label.250 Some scholars suggest that NIH, private
foundations, and the pharmaceutical industry should “study longterm clinical and developmental effects of antipsychotic use by
children,251 and . . . support research on potentially safer
pharmacological interventions, as well as psychosocial
interventions for disruptive behavior and emotional disorders of
children.”252
In the early 2000s, fraudulent positive-clinical-trial results for
the antidepressants Paxil and Zoloft allowed these two
medications, later shown to cause suicidal thinking and addictive
249. Id.
250. Id. (citing Helen Egger, M.D., Chief of Child and Family Mental
Health and Developmental Neuroscience in the Department of
Psychiatry and Behavioral Sciences at Duke University Medical
Center).
251. Wacker et al., The Protection of Subjects in Clinical Research, in
DRUG INJURY: LIABILITY, ANALYSIS AND PREVENTION, 95–109, 99
(James T. O’Donnell ed., 3d ed. 2012) (“Despite the need for
pediatric drug studies, many argue that clinical studies put children
at risk, for a multitude of reasons. Others believe that the benefit
outweighs the risk. After all, clinical trials place a small number of
children at risk (in a controlled environment). Furthermore, the
children enrolled in clinical studies will have illnesses and, therefore,
stand to (hopefully) benefit from the experimental treatment. The
ultimate benefit will be appropriate pediatric labeling for the drug
and safe use on children in the future.”). In 2013, FDA adopted a
final version of rules requiring that drug trials in the child
population comply with Subpart D of HHS regulations, providing
additional protections for research involving children. COLEMAN ET
AL., supra note 10, at 592 (citing Food and Drug Administration,
Additional Safeguards for Children in Clinical Investigations of
Food and Drug Administration-Regulated Products, 78 Fed. Reg.
12,937 (Feb. 26, 2013)). Research can (and probably should) be
conducted in child populations with extra safeguards in place. See
id. at 590–91.
252. Use of Antipsychotic Medications for Nonpsychotic Children: Risks
and Implications for Mental Health Services, in 18 THE BROWN
UNIV. CHILD & ADOLESCENT PSYCHOPHARMACOLOGY UPDATE 6
(Mar. 2016) (Jeffrey I. Hunt, M.D. ed.) [hereinafter Brown Univ.
Antipsychotics] (citing Daviss et al., Use of Antipsychotic
Medications for Nonpsychotic Children: Risks and Implications for
Mental Health Services, PSYCHIATRY SERV. (Jan. 4, 2016)).
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qualities in children, to be prescribed off label to this vulnerable
group.253 These examples of off-label antidepressant use in
children showcase “the greatest known divide in medicine”—the
discrepancies between what is reported in scientific literature and
what raw data actually show—and this problem likely extends to
all types of off-label treatments.254 This fraudulent activity shows
“how far our scientific standards have slipped and how this
impinges on our ability to care for some of the most vulnerable
people there are.”255
One of our most vulnerable populations, children in foster
care or the juvenile justice system, are the most likely to be
prescribed antipsychotic medication.256 A 2011 Government
Accountability Office (GAO) report found that in 2008, children
in foster care in five sample states were prescribed antipsychotic
drugs at higher rates than children not in the foster care
system.257 The report found that foster children were sometimes
four-and-a-half times more likely to be prescribed psychotropic
medication than their non-foster child counterparts within the
Medicaid system.258 The report also found that hundreds of
children in the five states had drug regimens of five or more
psychotropic drugs—including antipsychotics—despite the fact
that there is no medical evidence supporting concurrent use of
this many drugs by children.259

253. WHITAKER & COSGROVE, supra note 124, at 102–07.
254. HEALY—PSYCHIATRIC DRUGS, supra note 171, at 148–49.
255. Id. (“[t]he published papers endorsing the use of Paxil, Prozac, and
Zoloft remain in print in the best journals and continue to fuel a
boom in off-label sales of these drugs to children. There have been
efforts to get [the fraudulent] study retracted but these have failed.
It continues to be built into guidelines supporting the use of
antidepressants for children.”).
256. Brown Univ. Antipsychotics, supra note 252, at 6.
257. U.S. GOV’T ACCOUNTABILITY OFF., GAO-12-201, FOSTER
CHILDREN: HHS GUIDANCE COULD HELP STATES IMPROVE
OVERSIGHT OF PSYCHOTROPIC PRESCRIPTIONS 12 (2011)
[hereinafter GAO-12-201]. The children studied in the GAO
report—both those in foster care and not in foster care—were
enrolled in the Medicaid programs of Florida, Massachusetts,
Michigan, Oregon, and Texas. Id. at 8.
258. Smith, supra note 170.
259. GAO-12-201, supra note 257, at 14.
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The drastic increase (an approximate tripling) in
prescriptions of antipsychotic drugs to children since the early
2000s is not the result of a sudden schizophrenia epidemic or other
forms of serious mental illness in children. Rather, it stems from
doctors’ use of these medications to “treat” behavioral issues, a
“treatment” that FDA has not approved.260 A disproportionate
number of these prescriptions are being written for disadvantaged
poor and minority children as young as age 2.261 Economically
disadvantaged children are increasingly vulnerable to the effects
of medications because of their developing brains and bodies, and
also because of stigma attached to mental illness,
behavioral/adjustment issues, and the condition of living in
poverty.262
According to a related 2015 Department of Health and
Human Services Office of Inspector General (OIG) study on
Medicaid-enrolled children, two or more quality-of-care concerns
were found in 49 percent of claims for SGAs, and 53 percent of
claims were identified as lacking monitoring for physiological and
behavioral changes,263 including measuring of height and weight,
taking vital signs and blood pressure, noting abnormal
involuntary movements, ordering laboratory tests (for example,
tests of liver function, and for blood glucose and lipid levels), and
electrocardiograms.264 Amid the overwhelming lack of monitoring,
reviewers identified failure of healthcare providers to recognize or
manage side effects of antipsychotic use, such as akathisia,
significant weight gain, insomnia, and edema.265 Only eight
percent of claims made for SGAs were related to prescriptions for
the “limited number of medically accepted pediatric

260. Too Many Kids, supra note 248.
261. Id.
262. See id.
263. U.S. DEP’T HHS, OFFICE OF INSPECTOR GENERAL, OEI-07-12-00320
EXECUTIVE SUMMARY: SECOND-GENERATION ANTIPSYCHOTIC DRUG
USE AMONG MEDICAID-ENROLLED CHILDREN: QUALITY-OF-CARE
CONCERNS 5, 9, 12 (2015), available at https://oig.hhs.gov/
oei/reports/oei-07-12-00320.pdf [https://perma.cc/HV7X-5BKZ]
[hereinafter OEI-07-12-00320]. The five States included in the OIG
study were California, Florida, Illinois, New York, and Texas.
264. Id. at 12.
265. Id.
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indications.”266 Among the other ninety-two percent of claims,
ones not related to prescriptions for medically recognized
pediatric indications, SGAs most commonly were prescribed to
treat “bipolar disorder (20 percent), mood disorders (13 percent),
and autism spectrum disorders (8 percent).”267 While the state of
New York’s Medicaid coverage policy mandated that payment
would only issue for SGAs prescribed for “medically accepted
indications,” the state program violated its own policy and paid
over 3,300 claims, totaling $773,607.00.268
Three of the SGAs included in the OIG study had FDA
warnings about an increased chance of suicidal ideation and
behavior in children, adolescents, and young adults being treated
with these antipsychotics while suffering from major depressive
disorder or other psychiatric disorders.269 However, FDA warnings
do not prohibit physicians from prescribing drugs, despite specific
warnings, if according to the physician’s judgment, the benefits
outweigh the risks.270 Thirty-seven percent of claims identified in
the study were for SGAs prescribed to treat the specific conditions
about which FDA had warned: for major depressive and other
psychiatric disorders.271 The report suggested that all children
prescribed the warned-of antipsychotics, regardless of their
precise diagnosis, need to be properly monitored for suicidal
ideation and all other side effects.272
It is common and legal for U.S. physicians to prescribe for
children drugs that have only been approved for adults.273 The
physician’s ethical dilemma is to withhold a drug that has not
been proven safe but that may also be capable of curing disease
or alleviating symptoms.274 While such practices may have begun,
266. Id.
267. Id.
268. Id. at 13. New York State Medicaid staff stated that because of the
lack of diagnosis information on drug claims, the strict coverage
policy was difficult to enforce absent a medical record review.
269. Id. at 14.
270. Id.
271. Id. Notably, the broad sweeping “other psychiatric disorders” could
apply to any child with any sort of mental health condition.
272. Id.
273. Wacker et al., supra note 251, at 99.
274. Id.
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with at least some level of evidence in treating a “small sub-group
of youth with significant developmental disabilities,” off-label
antipsychotic prescribing has been expanded to treatment of
“cognitively normal” young people with a paucity of evidence on
safety and efficacy.275 In comparing two studies, one looking at
the period 2005-2009 and one from a decade earlier, antipsychotic
prescription increased by approximately 85 percent in the child
and adolescent population, a much higher increase than seen in
the adult population.276
Clinical trials support the efficacy of some antipsychotics for
irritability associated with autism in adolescents and children;
specifically, risperidone for children as young as age five, and
aripiprazole for those six years old and up.277 Clinical research also
supports the efficacy of certain antipsychotics in treating child
and adolescent bipolar mania and schizophrenia.278 However,
antipsychotics are not approved by FDA to treat attention-deficit
hyperactivity disorder (ADHD).279 Nonetheless, as of 2015,
research280 noted that boys ages 11–17 diagnosed with ADHD
275. Too Many Kids, supra note 248 (quoting David Rubin, M.D.,
Associate Professor of Pediatrics at the Perelman School of
Medicine at the University of Pennsylvania).
276. Id.
277. Study Finds Most Young People Treated with Antipsychotics Lack
MH Diagnosis, 25 MENTAL HEALTH WKLY., August 17, 2015, at 1
(Valerie Canady et al., eds.) [hereinafter Mental Health Weekly]
(citing Mark Olfson et al., Treatment of Young People with
Antipsychotic Medications in the United States, 72 JAMA
PYSCHIATRY 867 (2015)); see also Too Many Kids, supra note 248
(“Schizophrenia is rarely diagnosed until adulthood, for example.
Bipolar disorder is estimated to affect less than 3% of teens,
according to the National Institute of Mental Health, but the exact
prevalence is unknown because of its difficulty to diagnose in
children. That’s partly because the symptoms are less clear and
may overlap with other conditions such as ADHD. And while about
one in 110 children have some form of autistic disorder, only about
30% are affected by the aggressive impulse behavior antipsychotic
drugs have been approved to treat.”).
278. Id.
279. Mental Health Weekly, supra note 277, at 2.
280. Id. at 3 (“Researchers noted that in the merged 2009 medical claims
and LRx sample, most of the younger children (60%), older children
(56.7%), adolescents (62%) and young adults (67.1%) treated with
antipsychotics had no outpatient or inpatient claim that included
a mental health diagnosis. The study found that among
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represented the highest use of antipsychotic treatments in the
studied population.281
There is concern among some in the psychiatrist community
about the extent of off-label prescription of antipsychotics to
children.282 While at risk for all the adverse side effects discussed
above in the context of adult patients prescribed antipsychotics,
both weight gain and hormonal changes occur more significantly
in children than in adults.283 Additionally, the younger the patient
prescribed antipsychotics off label is, “the more . . . [the drug] can
affect the developing brain.”284 Especially in the context of
children, long-term effects are harder to determine because their
current life experience is short and cannot yet have been studied.
Thus, risks have “not been assessed in longitudinal follow-up
studies conducted with larger samples.”285
Off-label use of antipsychotics in the child population is
problematic because it is becoming commonplace, even while
studies with this population are lacking. In the case of other drugs
commonly prescribed off label for children, for example, to treat
physical ailments, there is generally evidence of safety and
efficacy through studies with adult populations. In the case of offlabel use of antipsychotics, there are no underlying studies with
adults, so the drugs are not proven safe or effective in any age
group. And yet, some of the most vulnerable in the U.S.
population—children who are poor—could be viewed to be
serving as “human subjects” in an unofficial experiment to test
safety and efficacy—at no cost to pharmaceuticals manufacturers.
antipsychotic-treated children and adolescents with mental
disorder claims, the most common diagnosis was ADHD (younger
children, 52.5%; older children, 60.1%; adolescents, 34.9%).
Depression was the most common diagnosis among young adults
(34.5%), followed by bipolar (26.6%) and anxiety disorder
(22.9%).”).
281. Id. at 2 (“Antipsychotics are used to manage aggression and other
symptoms in ADHD.”).
282. Minji Sohn et al., Nation Trends in Off-Label Use of Atypical
Antipsychotics in Children and Adolescents in the United States,
95 MED. 1, 1 (2016).
283. Brown Univ. Antipsychotics, supra note 252, at 5.
284. Too Many Kids, supra note 248 (quoting Christopher Bellonci,
M.D., Assistant Professor at Tufts University School of Medicine).
285. Brown Univ. Antipsychotics, supra note 252, at 5.
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4.

The Elderly and Poor

Although studies show an increased risk of death for elderly
patients taking antipsychotic drugs, nursing home physicians
across the United States continue to prescribe these drugs to
“treat” psychosis and behavioral problems caused by dementia.286
All antipsychotic drug labels carry the strongest warning, called
a “black box” warning, about the risk of stroke and death when
taken by patients with dementia.287
In the context of evaluating Medicare claims, the OIG study
above noted that an earlier OIG report on SGA prescriptions for
elderly nursing-home residents found that fourteen percent of
those residents had Medicare claims for SGAs.288 Eighty-three
percent of them were prescribed SGAs off label, and eighty-eight
percent were for the very conditions identified in the FDAmandated black-box warning, like dementia.289 Further, the
investigation found that over one-in-five Medicare claims for
antipsychotics failed to comply with federal guidelines that
prohibit unnecessary or excessive medication of persons in nursing
homes.290
It is often the case that antipsychotics are prescribed and
administered to elderly patients, especially those in nursing
homes, in order to sedate and confine the resident—which lessens
the care-burden on staff. Treating a mental illness like
schizophrenia is generally not the purpose.291 According to the
most recent APA guidelines on using antipsychotics to treat
agitation or psychosis in dementia patients, these drugs should
only be used in emergency settings when symptoms are severe
and situations dangerous.292 Yet, interestingly, under Medicare’s

286. McCarron, supra note 165, at 484.
287. Antipsychotic Drugs a Last Resort, supra note 229.
288. OEI-07-12-00320, supra note 263, at 6.
289. Id.
290. Smith, supra note 170.
291. See HUM. RIGHTS WATCH, supra note 191.
292. Martin R. Farlow & Tatyana A. Shamliyan, Benefits and Harms
of Atypical Antipsychotics for Agitation in Adults with Dementia,
27 EUR. NEUROPSYCHOPHARMACOLOGY 217–231 (2017) (citing V.I.
Reus et al., The American Psychiatric Association Practice
Guideline on the Use of Antipsychotics to Treat Agitation or
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Part D prescription-drug plan, antipsychotics are one of six drugs
considered to belong to a “protected class,” meaning that
“permissive compendium ratings may virtually guarantee
reimbursement of off-label prescription claims.”293
In the case of poor families, they may lack resources and the
ability for self-advocacy, and prescribers may opt to use
antipsychotics as a quick and inexpensive fix to control
behavior.294 Economically disadvantaged people may lack access
to mental health professionals who provide psychosocial
interventions,295 either because these professionals do not practice
in underserved neighborhoods, or they do but their fees are
exorbitant and prohibitive.296
A lack of financial resources appears to be a relevant factor
in the likelihood that one will be prescribed an antipsychotic off
label. Also significant is one’s ability to self-advocate, or the
absence of such ability. Elderly persons living in nursing homes,
children, and people who are economically disadvantaged lack
agency due to various circumstances—confinement to the facility
due to infirmity, no legal autonomy, and insufficient financial
means for alternative treatment—and this makes these groups
uniquely vulnerable to receiving prescriptions for drugs that are
not supported by evidence of safety and efficacy.
This section reviewed the ways in which antipsychotics use
has been pushed to the limits, and beyond. Medications that were
originally developed to treat a specific set of symptoms and
certain severe mental illnesses have quietly gained legitimacy for
the treatment of less burdensome diseases, with no evidence of
safety and efficacy. The balancing of risks and benefits, especially
where serious and long-lasting side effects are implicated, should
become a very different equation in the case of the psychiatric
Psychosis in Patients with Dementia, 173 AM. J. PSYCHIATRY 543–
546 (2016)).
293. Richard P. Paczynski et al., Quality of Evidence in Drug
Compendia Supporting Off-Label Use of Typical and Atypical
Antipsychotic Medications, 24 INT’L J. RISK & SAFETY MED. 137,
143 (2012).
294. Brown Univ. Antipsychotics, supra note 252, at 6.
295. Id.
296. See Too Many Kids, supra note 248 (citing David Rubin, M.D.,
Associate Professor of Pediatrics at the Perelman School of
Medicine at the University of Pennsylvania).
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patient who does not suffer from psychosis. But the market is
growing exponentially, and beginning with the elderly and the
poor, the U.S. government, through Medicare and Medicaid, is
subsidizing this expansive use at no cost to drug manufacturers.
The questions next addressed are how did we get here, and where
were the regulators?

III. Off-Label Safety and Efficacy: Who’s Really
in Charge Here?
Significant
evidence
shows
that
pharmaceuticals
manufacturers manipulated and corrupted clinical trial data and
“purchased” expert consensus guidelines for the indications and
patient populations ultimately receiving FDA approval relating
to antipsychotics, i.e., treatment of psychosis in the patient
population suffering from schizophrenia.297 Because these data on
safety and efficacy were distorted for the intended treatment
purpose and population, this creates an even more suspect and
potentially dangerous outcome for patients prescribed these drugs
off label.
A. Anecdotal “Evidence”

The types of professional writings often laying the
groundwork for future, rampant off-label uses range from medical
journal articles describing substantive clinical research on
evidence-based off-label uses to anecdotal clinical case studies
regarding “successful” individual off-label use.298 Determining the
true sources of information can be a challenge, as ghostwriting is
a critical problem. In the medical setting, ghostwriting occurs
where the actual author of a medical article is not credited—
thought by some scholars to be an effort to veil pharmaceutical
industry involvement and create an appearance of sponsorship by
academia.299 Under such arrangements, a medical writer drafts the
article and it is attributed to a prominent doctor, often one at a
major university. While scientific journals often inform about
official clinical study results, there are other types of scientific
writings, such as editorials, letters to editors, and review
297. WHITAKER & COSGROVE, supra note 124, at 149–50.
298. Barkus & Derian, supra note 20, at 863.
299. See ELLIOTT, supra note 86, at 33; see also WHITAKER & COSGROVE,
supra note 124, at 158–59.
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articles.300 These ghostwritten articles and letters influence
physicians’ decisions to prescribe drugs off label.301 It is estimated
that off-label prescription decision-making is informed by these
ghostwritten articles in “up to half of all medical prescriptions—
and more for children.”302 Notably, in the cases of the
antidepressants Paxil and Zoloft,303 ghostwriters produced all of
the published studies.304
In our culture, there is a tendency to associate science with
truth, and commerce as something that needs some regulation by
government.305 “The tension between science and commerce”306 is
present at the intersection of the practice of medicine and the
business of major pharmaceutical companies. There seems to be
a general inclination in the U.S. to extend the notion that “science
is truth” to “scientists are truthful.”307 Science, however, is quite
commercialized.308 A pharmaceuticals company will hire science
writers to present the company in the light it desires, and
favorable opinions are an assumed condition of continued
employment.309 Despite this potential bias, the physician “author”
may give the article only a cursory review before signing her name
to it. These articles have wide and enduring impacts, often

300. ELLIOTT, supra note 86, at 36 (“Review articles . . . summarize the
current state of knowledge about an illness or a therapy based on
the author’s reading of the published literature.”). Elliott notes,
however, that not all ghostwriting is unethical. Id.
301. HEALY—PSYCHIATRIC DRUGS, supra note 171, at 110–11.
302. Id. at 111.
303. See discussion supra, Part II.B.3.
304. Id. at 149.
305. See generally, id. at 128.
306. ELLIOTT, supra note 86, at 34.
307. Id.
308. Id.; see also Anthony Fletcher & Philip Bourne, Ten Simple Rules
to Commercialize Scientific Research, 8 PLOS COMPUTATIONAL
BIOLOGY 1 (2012).
309. ELLIOTT, supra note 86, at 36 (quoting medical writer David
Bronstein (pseudonym)). Many in the industry view the medical
ghostwriter as similar to a secretary, or, being generous, as an
editor. Id. at 33.
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informing decisions on inclusion of off-label uses in the
pharmaceuticals compendia.310
Some scholars assert that institutional corruption within
psychiatric professional organizations affects formulation of
consensus practice guidelines (CPGs).311 While the APA’s mission
is “to provide ‘humane care and effective treatment for all persons
with mental disorders,’” pharmaceutical-company funding and
guild interests are alleged to have compromised that public health
agenda.312 Rather than meeting its obligations to society to
conduct objective research and disseminate only “fully accurate
information on the efficacy and safety of [antipsychotic]
medications,” the APA has allowed (and in some instances
facilitated) distortions of “scientific truths” that have led to
“significant social injury.”313 Prior to issuance of CPGs, experts
in the field may create “consensus guidelines” that influence
treatment, and corruption also has been documented at this
point.314
Whether included in the compendia or not, a well-intentioned
individual psychiatrist may read a peer-reviewed journal article—
funded by the pharmaceuticals industry and sanctioned by the
APA or leaders in the field—and believe he is educating himself
about current trends and successes with a particular off-label
treatment. Thus, individual-practice psychiatrists who are “surely
motivated to see their patients do well, are harmed by this
corruption, as well.”315 Some physicians will rely on “experience,
anecdotal reports, and opinion leaders to guide their treatment
310. See, e.g., id. at 37–38.
311. WHITAKER & COSGROVE, supra note 124, at 148–49.
312. Id. at 4–7.
313. Id. at 5–6.
314. Id. at 149–50 (discussing Janssen’s unrestricted $450,000 grant to
three leading academic institutions that employed three prominent
academic psychiatrists who “coincidentally” produced an expert
consensus guideline on the use of Janssen’s Risperdal as a first-line
treatment for schizophrenia, later published in the Journal of
Clinical Psychiatry; through another financial arrangement with
the three psychiatrists, it is alleged that Janssen paid them over
$425,000 for speaking engagements to influence state governments’
and
providers’
adoption
of
the
consensus
guideline
recommendations).
315. Id. at 159.
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decisions, often failing to demand solid evidence for their
prescribing practices.”316 Alone—with no malfeasance on the part
of pharmaceuticals manufacturers or abdication of responsibility
on the part of the APA—this professional approach to clinical
knowledge can lead to widespread inappropriate prescribing.317
Whether or not “bad actors” have intentionally manipulated
prescribing practices, psychiatrists prescribe antipsychotics off
label to nonpsychotic patients with no solid research basis. This
has cascaded into widespread acceptance of this off-label use and,
ultimately, has modified the standard of care.
B. Compendia May be Informed by Ghostwriting and
Unsubstantiated Evidence

As stated above, “scholarly” articles that may be improperly
influenced by the pharmaceuticals industry, and allowed by either
the academic psychiatrist’s inattention to detail or his greed,
often inform decisions about whether to include off-label uses in
the pharmaceuticals compendia. Compendia are compilations
that “describe the evidence and make recommendations regarding
different therapeutic applications of FDA-approved drugs.”318
Congress and the Centers for Medicare and Medicaid Services
(CMS) have officially designated several of the compendia as
authoritative to inform determinations regarding off-label
prescription drug coverage.319 Both public and private insurers use
the drug compendia in making coverage determinations and the
compendia are regarded by some as having “de facto authority in
off-label reimbursement decisions across a variety of therapeutic

316. Dresser & Frader, supra note 115, at 479–80 (arguing that the
medical community has a responsibility to rectify situations where
off-label uses lack adequate evidentiary bases, stating that “[h]igh
quality evidence about off-label applications not only protects
patients from harmful and ineffective interventions, it increases
their access to beneficial treatments.”).
317. Id.
318. Paczynski et al., supra note 293, at 137.
319. Id.
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classes.”320 But evidence in the compendia has received scant
scrutiny and can be of poor quality.321
Clearly, the compendia play an essential role today in
evidence synthesis, coverage decisions, and prescription
utilization. Greater oversight and effort must be committed to
improving both the quality of evidence and transparency of its
evaluation as contained in the compendia.322 But it may already
be too late, as certain states have a preference favoring off-label
uses. For example, a New Hampshire statute requires payment of
insurance claims for off-label prescriptions if those non-approved
indications are listed in the compendia.323 This statute provides
guaranteed coverage for non-indicated uses so long as they are
included in one of the compendia or “medical literature,” which,
as discussed above, can be easily influenced by manufacturers
through ghostwritten articles later used as “evidence” of safety
and efficacy. This statutory scheme eliminates a potential
oversight role for insurance companies, and leaves drug
manufacturers in the driver’s seat.
C. Unfairness of Burdening Large Pharmaceuticals Manufacturers

There are valid safety and efficacy concerns about introducing
mind-altering chemicals approved for treating psychosis into the
320. Id. at 143.
321. Id. at 138; see also Dresser & Frader, supra note 115, at 479
(discussing a review of Medicare-approved compendia that found a
lack of consistency, quality, transparency and timeliness).
322. See Dresser & Frader, supra note 115, at 479. CMS’s Medicare
Evidence Development and Coverage Advisory Committee issued
guidelines in 2007 on ways to improve information quality and to
rationalize processes associated with including citations relating to
off-label therapies in the compendia, however, these guidelines
primarily applied to drugs used off-label in treating cancer.
Paczynski et al., supra note 293, at 138.
323. N.H. REV. STAT. ANN. § 415:6-g (1997) (“I. No insurer that issues
or renews any individual policy of accident or health insurance
providing benefits for medical or hospital expenses and providing
coverage for prescription drugs shall: (a) Exclude coverage for any
such drug for a particular indication on the ground that the drug
has not been approved by the Food and Drug Administration
(FDA) for that indication, if such drug is recognized for treatment
of such indication in one of the standard reference compendia or in
the medical literature.”).
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mind of nonpsychotic patients. Multiple studies that compared
adverse events relating to approved versus off-label drug uses
have shown that there is a higher incidence of adverse drug
reactions among patients prescribed medications for off-label
purposes.324 However, some engaged in the debate surrounding
off-label uses suggest it is not reasonable to expect
pharmaceuticals companies to devote time and financial resources
to support additional clinical trials to prove the safety and
efficacy of approved drugs for additional purposes.325
Those making such assertions offer the rationale that after
spending hundreds of millions of dollars supporting the drug’s
original New Drug Application (NDA), a requirement for
additional studies would necessitate replication of efforts and
would cost manufacturers additional “hundreds of millions of
dollars in new testing and take years.”326 But this is not
necessarily true. For example, there exists an abbreviated
pathway under FDCA §505(b)(2) for approval of drugs, where an
“applicant is not restricted to reliance on published studies, but
may also rely on previous FDA findings of safety and efficacy for
another applicant’s drug based on unpublished data in FDA’s
files that is no longer legally protected.”327 The 505(b)(2)
application also could be used where “an applicant that seeks to
market its version of an established drug for a new therapeutic
indication or with some other modification requiring new clinical
studies [wishes to] rely on relevant safety findings on the drug in

324. Aishwarya Vijay et al., Patterns and Predictors of Off-Label
Prescription of Psychiatric Drugs, 13(7) PLOS ONE 2 (2018).
325. Michael Ollove, Pressure Mounts to Lift FDA Restrictions on OffLabel Drugs, WASH. POST (Oct. 7, 2017, 12:00 PM),
https://www.washingtonpost.com/national/health-science/
pressure-mounts-to-lift-fda-restrictions-on-off-label-drugs/2017/
10/06/568204a0-a2f6-11e7-8cfe-d5b912fabc99_story.html?utm_
term=.46e5b955401e [https://perma.cc/B4GQ-LX28] (reporting
views of Peter Pitts, president and co-founder of the Center for
Medicine in the Public Interest, a nonprofit research and advocacy
organization funded by the pharmaceutical industry).
326. Id.
327. Geoffrey M. Levitt, The Drugs/Biologics Approval Process, in A
PRACTICAL GUIDE TO FDA’S FOOD AND DRUG LAW AND
REGULATION 125, 160 (Kenneth R. Piňa & Wayne L. Pines, eds.,
2017).
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a previously approved NDA.”328 If the 505(b)(2) process is not
unduly burdensome for companies that want to market an
approved drug for a new indication, then why would it be unduly
burdensome to require the same of the original drug sponsor in
order for their approved drug to be used for a new indication?
This option would substantially decrease the cost-burden on the
original drug sponsor,329 while also allowing for FDA oversight in
the matter.330 It is illogical that the original sponsor is allowed to
bypass FDA scrutiny through off-label uses from which the
sponsor reaps financial rewards, and that FDA instead gives
deference to determinations that may be supported only by a
physician’s ill-informed beliefs about safety and efficacy.
In the context of the off-label promotion debate, those
opposing such promotion argue that if a drug has not been FDAapproved for off-label uses, then the drug manufacturer has not
provided evidence of safety and efficacy for those other uses.331 In
opposing off-label promotion, FDA itself has taken the stance
328. Id. (emphasis added).
329. See U.S. FOOD & DRUG ADMIN., APPLICATIONS COVERED BY
SECTION 505(B)(2): DRAFT GUIDANCE FOR INDUSTRY 3 (1999)
(“This use of section 505(b)(2), described in the regulations at 21
CFR 314.54, was intended to encourage innovation without
creating duplicate work.”). Note that this reference from 1999 was
draft Guidance.
330. See 21 C.F.R. § 314.54 (2019), which states:
PART 314—APPLICATIONS FOR FDA APPROVAL TO MARKET A NEW
DRUG. § 314.54 Procedure for submission of a 505(b)(2) application
requiring investigations for approval of a new indication for, or
other change from, a listed drug. (a) The Federal Food, Drug, and
Cosmetic Act does not permit approval of an ANDA [Abbreviated
New Drug Application, used for generics manufacturing] for a new
indication, nor does it permit approval of other changes in a listed
drug if investigations, other than bioavailability or bioequivalence
studies, are essential to the approval of the change. Any person
seeking approval of a drug product that represents a modification
of a listed drug (for example, a new indication or new dosage form)
and for which investigations, other than bioavailability or
bioequivalence studies, are essential to the approval of the changes
may, except as provided in paragraph (b) of this section, submit a
505(b)(2) application. This 505(b)(2) application need contain only
that information needed to support the modification(s) of the listed
drug.
331. Ollove, supra note 325 (quoting Allison Zieve, director of the
litigation group at Public Citizen).
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that off-label promotion may result in patients (1) being
prescribed unproven therapies, or (2) being prescribed therapies
with less efficacy or more risk than FDA-approved therapies.332
FDA stands firm behind its concern that off-label promotion may
disincentivize pharmaceutical companies from conducting
additional safety and efficacy studies.333 These same arguments
could be made in the context of off-label prescription.
D. Psychiatrists Behind Closed Doors

During the nineteenth century, research mostly was
conducted on a small scale, “with individual physicians trying out
one or another remedy or procedure on a handful of persons.”334
Experimentation began in the investigator’s home, using his own
body, or those of relatives and neighbors.335 While
experimentation in current times brings to mind large-scale
studies sponsored by pharmaceuticals manufacturers, much of offlabel prescription is experimental in nature. The individual
psychiatrist tinkers with different psychotropic medications—
including antipsychotics—attempting to treat or manage a
nonpsychotic patient’s mental ailments. This is perfectly legal:
But when experimentation in medical practice336 means
potentially altering the core of a person’s being—the mind—there
should be some sort of heightened oversight.
1.

Innovative Treatment or Experimentation?

Off-label use sometimes constitutes the best treatment for
certain patients under given circumstances and may also provide
an
important
means
of
discovering
effective
new
therapies.337 Scholars of research ethics understand how difficult
332. Wayne Pines, Regulation of Promotion and Distribution, in A
PRACTICAL GUIDE TO FDA’S FOOD AND DRUG LAW AND
REGULATION 439, 440, (Kenneth R. Piňa & Wayne L. Pines, eds.,
2017).
333. Id.
334. Rothman, supra note 221, at 21.
335. Id.
336. See Mithani, supra note 1, at 577 (noting the Fenfluramine example
discussed, supra, at Part I.B.).
337. See Dresser & Frader, supra note 115, at 476; Stoffelmayr, supra
note 37, at 279 (citing Christopher, supra note 104, at 249 (for the
statement that anecdotal evidence from general practice medicine
suggests off-label use often “leads to serendipitous drug discovery”)
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it can be to draw clear distinctions between human
experimentation and medical treatment, and that innovation that
is neither clearly research nor treatment makes discerning those
distinctions even more difficult.338 One could argue that given the
theoretical assumptions of the prescribing physician and the lack
of scientific support, off-label prescription itself should be
categorized as “experimental or investigational,” and this
categorization would then mandate that physicians obtain
consent similar to that required in research—most likely
written—from patients.339 Might there be a middle ground,
requiring more than regular patient consent but less than the
consent mandated in clinical drug trials?
The essential question is, in using antipsychotic medications
off-label in private practice, when does the individual
psychiatrist’s treatment of the individual patient become less
about treatment and more about innovation, or, taken a step
further, actual experimentation? Some scholars assert that
physicians are conducting uncontrolled and unregulated
experimentation within private practice; that patients are being
experimented on because clinical research prior to clinical use is
lacking.340 As Dr. Sidney Wolf of Public Citizen observed, “huge
numbers of people are going to be made guinea pigs for
unapproved uses of drugs.”341 Others believe, however, that there
is nothing to fear. For example, one U.S. Senator—who was also

and Shapiro, supra note 104, at 809 (“effective off-label drug uses
may be discovered when physicians try therapies based on informal
theorizing, or when a patient with multiple conditions receives a
drug to treat one condition and another condition unexpectedly
improves as well.”)).
338. King, supra note 64, at 573.
339. Mithani, supra note 1, at 578; see also Barkus & Derian, supra note
20, at 863.
340. Johns, supra note 27, at 979 (quoting Paul D. Stolley, Chair of
Epidemiology and Preventative Medicine, University of Maryland
School of Medicine).
341. O’Reilly & Dalal, supra note 92, at 307; see JM Beck & ED Azari,
FDA, Off-Label Use, and Informed Consent: Debunking Myths and
Misconceptions, 53 FOOD & DRUG L. J. 71, 104 (1998) (quoting
Christopher, supra note 104, at 255, explaining that federal
regulations requiring informed consent for FDA trials do not apply
to off-label treatments); see also Teo, supra note 35, at 319, 323.
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a physician—offered reassurance from the Senate floor that
amounted to paternalistic “because I say so” reasoning:
I have some responsibility to define for my colleagues what
off-label means. Off-label scares people. Is it somebody
going in some secret closet and pulling out a medicine and
using it? No, it is not. That is why extra-label is probably
a better term. But right now off-label is something that we
in the medical profession understand is used routinely in
the pediatric population and, as mentioned earlier, for
inpatient hospitalization. Probably 50 percent of all
pediatric drugs prescribed are off-label. So it is not a term
to be scared of or to fear.342

In the context of surgery, innovation and improvisation are
expected, partly because each patient’s anatomy is unique. Yet,
medicine’s history is replete with examples of “medical innovators
from all specialties, and popular culture likewise abounds with
images of the physician-scientist as Lone Ranger.”343 Perhaps
innovation is common in the realm of psychopharmacologic
practice, where one FDA-approved antidepressant works to treat
one patient’s depression and another approved antidepressant
does not. Because of this, the psychiatrist’s approach must often
be “let’s try and see” if a given psychotropic medication will be
effective for this particular patient. But when moving outside of
FDA-approved uses of a psychotropic, such as the antipsychotic
Risperdal, and prescribing and introducing the drug’s chemicals
into a lucid mind, is this a step too far? Is there, or should there
be, a distinction between trying to eradicate a bacterial infection
or cancerous cells that are not supposed to be in the patient’s
body with a drug not approved for such purposes—when nothing
else works—and introducing mind-altering chemicals into the

342. 143 CONG. REC. S8165 (daily ed. July 28, 1997) (statement of Sen.
Frist).
343. King, supra note 64, at 574 n. 8 (“Even the FDA ‘treads lightly
upon the practice of medicine and surgery,’ thus implicitly
encouraging this overwhelmingly positive view of unregulated
innovation” (quoting Philip D. Noguchi, From Jim to Gene and
Beyond: An Odyssey of Biologics Regulation, 51 FOOD & DRUG L.
J. 367, 392 (1996)).

296

Health Matrix·Volume 30·2020
The Off-Label Loophole in the Psychopharmacologic Setting

patient’s blood system that will change the part of the patient
that uniquely defines her?344
This sort of tinkering with a person’s essence is more suspect,
and more in need of regulation. But the regulators are nowhere
to be found. This leaves the individual psychiatrist with a great
deal of power and discretion, and too often that discretion may
be informed by “scientific support” that is manufactured by drug
manufacturers.
2.

Our Most Vulnerable in Effect “Subjects” in Private Practice
“Clinical Trials”

Introducing chemicals into any person’s brain should be done
with great care and knowledge and should never amount to a
mere guess regarding safety and efficacy. But patients seem to
“receive the least regulatory protection in those cases where they
may need it the most—namely, when individual physicians may
haphazardly try out a different technique under the guise of
providing innovative therapy.”345 Just as with actual clinical trials
for a new drug or non-indicated use of an existing drug, targeting
vulnerable persons for disproportionate inclusion or exclusion in
studies is never appropriate.346 The same argument applies when
a certain vulnerable group or categories of vulnerable populations
are disproportionately prescribed a drug, such as an
antipsychotic, off label. This is precisely what is happening,
however, to the poor, the elderly, and children in foster care.
Collectively, these vulnerable individuals could be likened to
uninformed “subjects” in unregulated private practice “clinical
trials.”
The concept of individualized treatment in good medical
practice informs the physician’s ethical mandate to promote an
individual patient’s best interests and to respect his or her

344. Gabriel Lazaro-Munoz, Responsible Translation of Psychiatric
Genetics and Other Neuroscience Developments: In Need of
Empirical Bioethics Research, 17 AM. J. BIOETHICS 33, 33 (2017)
(quoting PRESIDENTIAL COMM’N FOR THE STUDY OF BIOETHICAL
ISSUES 11 (2014)) (“When you start tinkering with the
brain . . . it’s really tinkering with who you are.”).
345. Johns, supra note 27, at 979 (citing Lars Noah, Informed Consent
and the Elusive Dichotomy Between Standard and Experimental
Therapy, 28 AM. J. L. & MED. 361, 392–93, 399–400 (2002)).
346. COLEMAN ET AL., supra note 10, at 146.
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autonomy.347 A focus on the health and best interests of individual
patients is what distinguishes medicine from public health which,
instead, is concerned with the well-being of an entire community
or population.348 As noted by one prominent physician, “the
practice of medicine is carried out ‘on an individual basis, with
the best interests of the patient foremost in the practitioner’s
mind.’”349 In contrast, FDA stresses that clinical research is
designed to answer specific questions through experimentation
with numerous research volunteers.350 Other differences
highlighted by FDA are that clinical research requires written
informed consent and periodic, systematic assessment of patient
data, whereas medical treatment sometimes requires no informed
consent at all and patient assessment is done only as needed.351
Finally, in addressing the concept of “certainty,” FDA states that
while research “tests products and procedures of unproven benefit

347. Zettler, supra note 55, at 437 (citing BERNARD LO, RESOLVING
ETHICAL DILEMMAS: A GUIDE FOR CLINICIANS 12–14 (5th ed. 2013));
cf. Canterbury v. Spence, 464 F.2d 772, 780 (D.C. Cir. 1972)
(finding that physicians have a duty to obtain informed consent
from patients because “every human being of adult years and sound
mind has a right to determine what shall be done with his own
body”); see Samia A. Hurst & Marion Danis, A Framework for
Rationing by Clinical Judgment, 17 KENNEDY INST. ETHICS J. 247,
248–51 (2007) (discussing physicians’ obligations to both ration
healthcare resources and advocate for patients’ best interests)); see
also Teo, supra note 35, at 324.
348. Zettler, supra note 55, at 437 (citing LAWRENCE O. GOSTIN, PUBLIC
HEALTH LAW: POWER, DUTY, RESTRAINT 4 (2d ed. 2008)); see
COMM. FOR THE STUDY OF THE FUTURE OF PUBLIC HEALTH, INST.
OF MED., THE FUTURE OF PUBLIC HEALTH 3 (1988) (noting that
“public health does things that benefit everybody”); see also
Onyebuchi A. Arah, On The Relationship between Individual and
Population Health, 12 MED. HEALTH CARE & PHIL. 235, 235 (2009)
(contending that “population health calls up images of nonindividual health”).
349. Id. at 437 (quoting Jeffrey M. Drazen, Government in Medicine,
356 NEW ENG. J. MED. 2195, 2195 (2007)).
350. Clinical Research Versus Medical Treatment, U.S. FOOD & DRUG
ADMIN.,
https://www.fda.gov/patients/clinical-trials-whatpatients-need-know/clinical-research-versus-medical-treatment
[https://perma.cc/Z69C-CVZJ] (last updated Mar. 22, 2018).
351. Id.
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to the patient,” medical treatment “uses products and procedures
accepted by the medical community as safe and effective.”352
Though FDA has elected a hands-off approach to regulating
the practice of medicine, when that practice—intentional or not—
is no longer treating the individual but instead certain classes of
patients who coincidently are vulnerable, what principles should
apply? This appears to be an instance of innovation bordering on
experimentation (as opposed to individual treatment) with
vulnerable classes of patients as subjects. If FDA continues to
abstain from intervening, then one possible solution would be for
Congress to amend the FDCA. A focal point of any amendment
should be the Belmont Report’s distinction between medical
practice and research,353 with specific emphasis on the concept
that a medical-practice intervention should be reasonably
expected to succeed.354 If off-label prescription of antipsychotics
has no scientifically based evidence of safety and efficacy, then it
is not “reasonable” to believe that these drugs will be “successful”
in treating the nonpsychotic patient. Any amendment should
address this hybrid of the practice of medicine and conducting
research.355
3.

Likelihood that Vulnerable Populations Avail Themselves of
State-Law Remedies

Some commentators believe there is no need for federal
regulation: the “freedom accorded to physicians does not go
unsupervised, because the fear of tort liability and medical
malpractice claims serves as a check on the prescribing practices
of physicians.”356 As discussed above, there are many hurdles over
which a plaintiff-patient must leap in order to prevail in the
courtroom. These obstacles are magnified in situations involving
vulnerable populations who are suffering from some sort of mental
352. Id.
353. King, supra note 64, at 573 (citing to THE BELMONT REPORT, supra
note 64) (“The Belmont Report defines medical practice as
‘interventions that are designed solely to enhance the well-being of
an individual . . . and that have a reasonable expectation of
success.’”).
354. Id.
355. A more apt description might be “the practice of research.”
356. O’Reilly & Dalal, supra note 92, at 299; see also Teo, supra note
35, at 319, 322.
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illness and who are taking antipsychotics with various adverse
side effects. Civil litigation in such circumstances is a weak
solution to a hefty problem and places the onus on the debilitated
mental-health patient to stand up and fight.
If the nonpsychotic psychiatric patient is even aware of being
harmed by an antipsychotic, then the synergistic effects of the
psychiatric illness—depression, for example, where the patient
may lack motivation, have recluse-like behaviors, feel defeated,
and be unable to work—and the sedating nature of the
antipsychotic will render the patient unable to summon the
energy, drive, or financial means necessary to pursue litigation.
Attempts to right the wrong done to the patient are extremely
unlikely. The patient-plaintiff must somehow have the emotional
and financial resources (or the ability to locate and retain free
counsel through a legal advocacy group) to pursue litigation and
the mental wherewithal to withstand the rigors and repercussions
of litigation. Clearly, the hurdles for any monetary recovery are
exceedingly high.
Further, in cases of children (especially foster children) and
the elderly (who are dependent on others for daily needs and care,
and who lack agency due to age, status, or confinement to a
nursing home), the likelihood of these patients availing
themselves of remedies at law is extremely low. For poor patients
receiving health care through Medicaid, it may be fair to assume
that they lack the resources needed to initiate legal action in order
to recover for harm suffered from taking antipsychotics off label.
Regardless of who is ultimately held liable (if anyone or any
entity is, at all) the patient-plaintiff in a medical malpractice suit
must prove, by a preponderance of the evidence, the physician’s
negligence by establishing that: (1) the physician had a duty to
care for the patient; (2) the physician breached that duty; (3) the
injuries caused were the direct and proximate result of the
physician’s breach; and (4) the patient’s injuries are compensable
damages resulting from the physician’s malpractice.357 Perhaps
some of the most difficult elements in medical malpractice cases
are where a plaintiff must demonstrate a causal connection
between the injury suffered and the physician’s failure to obtain
informed consent or follow the standard of care.358 And then, of
course, the patient-plaintiff must locate and pay a forensic “non357. Najib, supra note 101, at 443 (footnotes omitted).
358. Barkus & Derian, supra note 20, at 863.
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treating expert” to testify that there was a misdiagnosis of the
condition and that treatment protocol for the correct diagnosis
would not have invoked use of the psychotropic drug in
question.359 Any legal victory would turn on expert testimony
establishing that prescription of the specific offending off-label
treatment demonstrated the physician’s lack of skill or
knowledge, or failure to exercise reasonable care or follow the
accepted standard of care.360 One must wonder how the mentally
ill patient, especially if prosecuting her case pro se, will find that
expert and have the financial resources to pay her.
Even in the plaintiff’s best possible legal outcome, although
the physician may be held liable for malpractice after harm is
caused due to use of a drug for an unapproved use, the obvious
reality is an after-the-fact award of money damages.361 Meanwhile,
the patient-plaintiff may have sustained irreversible physical
damage, endured years of lost productivity, and will carry the
emotional and societal stigma of having taken an antipsychotic.
The courts do not adequately prevent, or remediate after the
fact, the harms to nonpsychotic psychiatric patients from taking
antipsychotics off label. Suggestions that a psychiatric patient’s
right to pursue litigation can be a meaningful alternative to
regulation are either disingenuous or lack consideration of the
difficulties of navigating the U.S. legal system, especially as a
person living with mental illness.
Behind closed doors, psychiatrists are allowed broad
discretion in deciding what is best for individual patients. When
many psychiatrists are making the same decisions for many
individual patients without evidence of safety and efficacy, this
begins to look like sloppy research with many principal
investigators instead of evidence-based medical practice. There is
an important ethical obligation to protect our most vulnerable
patients but apparently little acknowledgement of the widespread
problem of off-label antipsychotic prescription, or any sense of
duty to address harms to affected populations.

359. Najib, supra note 101, at 443.
360. Helm, supra note 90, at 171.
361. Berry, supra note 16, at 37–38.
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IV. Who Protects the Most Vulnerable Patients?
Patients who suffer from severe mental illness should be
considered potentially vulnerable in both clinical research and
clinical practice. The federal government does little to protect
research subjects who may have “impaired decisionmaking
capacity” or are otherwise “vulnerable to coercion or undue
influence,” allowing broad discretion to institutional review
boards in determining if adequate protections are in place.362
Likewise, U.S. common law allows the treating psychiatrist wide
latitude when working with psychiatric patients. What might be
done, on either the federal and state levels (or both), to curb the
rampant off-label prescription of antipsychotics?
A. Why Psychiatrists Need More Regulation

Despite state informed-consent requirements, some
physicians habitually fail to properly and adequately warn
patients about risks and side effects associated with their
prescription medications.363 Psychotropic medications, and
antipsychotics in particular, produce numerous adverse side
effects. Perhaps these are worth the risk to the patient suffering
from schizophrenia, but for the patient not experiencing
psychosis, the risks may be unjustifiable where the supposed
benefit is only to manage—not treat or cure—a mood state. For
those patients, other alternatives may be available.
Unfortunately, one cannot depend on the psychiatrist always to
do what is in the patient’s best interest.
During the 1973 “Quality of Health Care—Human
Experimentation” hearing conducted by Senator Edward
Kennedy,364 certain testimony (while not pertaining to the FDCA)
illuminated problems that existed, and likely still exist, in
allowing physicians unbridled discretion in the practice of
medicine. In opening, Kennedy stated:

362. 45 C.F.R. § 46.107 (2019); 45 C.F.R. §§ 46.111(a)(3), (b) (2019).
363. Barkus & Derian, supra note 20, at 862. This does not pertain to
practices related to FDCA, but an analogous framework and lack
of government oversight are present.
364. ROTHMAN, supra note 221, at 184 (citing pts. 1–4, Hearings Before
the Senate Subcommittee on Health and the Committee on Labor
and Public Welfare, 93d Cong. (1st Sess. 1973)).
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Human experimentation is part of the routine practice of
medicine . . . . An absence of vigorous oversight, ‘coupled
with the most unlimited freedom of action which physicians
have in the treatment of their patients,’ allowed dangerous
practices, including the premature use of unproven and
untested drugs and procedures. The question, is whether or
not we can tolerate a system where the individual physician
is the sole determinant of the safety of an experimental
procedure. After all, it is the patients who must live the
consequences of that decision.365

At those same hearings, the then head of the National
Institute of Mental Health (NIMH), Bertram S. Brown, M.D.,
explained that the practices (even if experimental) of a private
physician were beyond NIMH’s grasp and control.366 The topic at
issue was psychosurgery and its use to treat aggressive,
uncontrollable, violent, and hyperactive behavior that did not
respond to other forms of treatment.367 Senator Kennedy
questioned Orlando Andy, M.D., a neurosurgeon from the
University of Mississippi and a major proponent of the surgery:
Q: Basically, then, you make an independent judgment
whether to move ahead on this kind of operation?
A: Yes. The final decision is always mine in terms of
whether or not an operation will or will not be done.

365. Id. at 184–85 (citing pt. 1, Feb. 21, 1973, p. 2 of Hearings Before
the Senate Subcommittee on Health and the Committee on Labor
and Public Welfare). Rothman includes examples where
experimental research and the practice of medicine intersect. In one
case, economically disadvantaged Mexican American women who
went to a clinic in Texas for contraceptives unknowingly were
subjects in an experiment “to identify whether the side effects of
contraceptive pills were physiological or psychological; half the
women were given contraceptive pills, the other half, placebos, in
order to allow the investigators to match reported side effects with
the active agent or the placebo.” Id. “The experiment itself and the
failure of the medical society to discipline the doctors involved not
only confirmed the idea that ‘poor minority people’ were
particularly liable to be abused but also demonstrated, yet again,
the inability of the profession to police its own members.” Id.
366. Id. at 186.
367. Id.
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Q: Do you have any board or panel that continues to review
the various bases for the psychosurgery in which you have
been involved?
A: No. We don’t have a board of supervisors or
investigators or peer review type of activity over what we
are doing.368

The doctor’s testimony raises the obvious ethical implications
of one physician having sole discretion to decide when a patient’s
brain will be surgically altered. With this surgeon, who regularly
tampered with the human brain in attempts to control antisocial
behavior, there was no oversight by a peer group or government
regulatory body.369 What was once done only through
psychosurgery can now, in essence, be accomplished with
psychotropic medications. With the effect of sedating and
controlling thoughts and behaviors of the patient suffering from
psychosis, for certain psychiatric patients, the numerous SGAs
can be a valuable resource. But could we endorse a little bit of
brain surgery to “fix or control” a nonpsychotic patient’s mood,
behavior or outlook when various alternatives, such as expensive
but effective psychotherapy, were available? The use of mindaltering medications instead of a scalpel is less extreme and less
invasive, yet antipsychotic medications sometimes have lifealtering chronic and irreversible side effects. Perhaps

368. Id. (citing the questioning of Dr. Orlando Andy during “Hearings
on Human Experimentation,” pt. 2, 23 Feb. 1973, p. 354).
369. Id. Rothman notes that while Senator Kennedy’s version of the
legislative proposal calling for the creation of a National
Commission for the Protection of Human Subjects passed the
Senate intact, the House had different ideas. The compromise
resulted in a temporary commission and advisory to the secretary
of HEW, with no independent enforcement powers. “Even in its
reduced state, however, the commission represented a critical
departure. First, it made apparent that the monopoly of the
medical profession in medical ethics was over. The issues were now
public and national—the province of an extraordinary variety of
outsiders . . . . Finally, although the commission was not
permanent and was charged to investigate not all of medicine but
only human experimentation, it had a vital and continuing
presence. When its mandate was about to expire in 1978, Kennedy
was able to transform it into the President’s Commission for the
Study of Ethical Problems in Medicine.” Id. at 189.
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psychiatrists’ habitual practice of prescribing antipsychotics off
label warrants closer scrutiny.
While there are plenty of honest and well-intentioned
physicians, “honesty is getting harder all the time.” 370 Whether
intentional or not, our country has created a medical system “in
which deception is often not just tolerated but rewarded,”371 and
through a series of social and legislative changes, medicine has
been transformed into a business permitted primarily to operate
within state boundaries and under self-regulation.372 Selfregulation, occurring via a state’s delegation of oversight
responsibilities to “the medical profession itself is another way
states oversee—or decline to oversee—medical practice.”373 Little
is done within the self-regulating psychiatric-physician group to
protect vulnerable nonpsychotic psychiatric patients from being
prescribed dangerous antipsychotics; rather, this physician group
has made such prescribing practices the standard of care, and has
made these patients “legally safe” specimens for informal,
unregulated “clinical drug trials.”
B. Congress and FDA Attempted to Close the Loophole

In 1968, a member of Congress alerted FDA of a medical
journal article that encouraged the use of Methotrexate—a drug
approved solely for treating particular cancers—to treat a nonlife-threatening skin condition, psoriasis.374 FDA had authorized
only “highly limited and tightly regulated investigational use of
the drug” in the treatment of psoriasis and rheumatoid
arthritis.375 While major side effects associated with Methotrexate
(for example, bone marrow suppression, leucopenia,
thrombocytopenia and anemia) might be outweighed by benefits
in the treatment of a cancer patient, these were not justifiable for

370. ELLIOTT, supra note 86, at xi.
371. Id.
372. Id.
373. Zettler, supra note 55, at 453.
374. Klasmeier & Redish, supra note 10, at 321 (citing New Drugs Used
for Nonapproved Purposes (Methotrexate for Psoriasis), Hearings
before a Subcomm. of the H. Comm. on Gov’t Operations, 92nd
Cong. 5 (1971)).
375. Id.
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a patient suffering a much less severe condition.376 In 1971, a
House subcommittee finally initiated hearings to consider the
unique questions and dangerous situation surrounding
Methotrexate, a drug legally marketed for restricted purposes
that was commonly being used to treat a different, non-indicated
(and thus, non-approved) medical condition.377
Dissatisfied with FDA’s handling of the issue (opting for a
physician educational campaign instead of inserting itself into the
doctor-patient relationship), members of Congress insisted that
FDA “develop a more coherent position on the Agency’s ability
to constrain prescriber decisions” in prescribing approved drugs
off label.378 While FDA’s witnesses asserted authority under the
FDCA for FDA to limit off-label uses, they conceded that FDA
officials had wavered on this position in the past.379 Congress
pressed FDA to establish clear policy regarding off-label use, and
FDA considered new regulations that would have given FDA the
ability to interfere directly in medical practice by controlling
particular off-label uses with which it disagreed. 380 However, “the
medical community continued its vigorous campaign of
resistance” to FDA’s appropriate efforts to constrain a
prescriber’s clinical judgment.381
Aiming to balance conflicting influences, FDA proposed a
new rule that would allow it to restrict physician-prescribing
under certain circumstances, although FDA strongly denied any
intention to interfere with the practice of medicine.382 The
proposed rule stated that if FDA “determined that an
‘unapproved use of a new drug may pose a danger to the patients
receiving the medication, [then] the agency may confine

376. Id.
377. Id. Eventually, FDA approved the use of Methotrexate for the
treatment of severe psoriasis. Gerald Weinstein, Methotrexate, 86
ANN. INTERNAL MED. 199, 199 (1977).
378. Klasmeier & Redish, supra note 10, at 322.
379. Id.
380. Id.
381. Id.
382. Id.; see Berry, supra note 16, at 9 n. 36 (citing Legal Status of
Approved Labeling for Prescription Drugs; Prescribing for Uses
Unapproved by the Food and Drug Administration, 37 Fed. Reg.
16,503 (1972)).
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distribution of the drug to specified channels or restrict the
physicians who are able to prescribe the drug.’”383 Under the
proposed rule, FDA would have had authority to limit the ability
to prescribe, dispense or administer certain drugs to physicians
possessing specified, specialized qualifications.384 This action
would have impacted physicians by effectively allowing FDA into
doctors’ offices, limiting their freedom to prescribe as they
deemed fit.385
Physicians “vociferously objected” to FDA’s interference with
physician decisions regarding which lawfully marketed drugs
would be used, for whom, and for what conditions.386 In an
attempt to satisfy both physicians and members of Congress,
FDA backed down,387 taking the position that “its statutory
authority to control the market introduction and labeling of new
drugs did not encompass the power to restrict the uses to which
approved drugs might be put.”388 FDA never issued the final
rule;389 instead, it issued a series of statements that appeared to
be an effort “to soothe the medical community,” denying that the

383. Berry, supra note 16, at 9.
384. Id. (footnote omitted).
385. Id.
386. Klasmeier & Redish, supra note 10, at 323, 356 n. 35 (“According
to David Kessler, FDA ‘was concerned’ about ‘improper
prescribing,’ but ‘was under great pressure from the American
Medical Association not to tell the doctor what he or she could
prescribe.’ Kessler indicated that FDA ‘chose to deal with the
problem [of off-label prescribing] as an educational matter.’”); See
also Lars Noah, Ambivalent Commitments to Federalism in
Controlling the Practice of Medicine, 53 U. KAN. L. REV. 149, 175
(2004) (“Physicians have gone so far as to pursue litigation against
the government when they viewed FDA initiatives as threatening
their right to practice medicine without federal interference.”).
387. Rodney A. Smolla, Off-Label Drug Advertising and the First
Amendment, 50 WAKE FOREST L. REV. 81, 90 (2015) (“[O]n the few
occasions in history in which the FDA has venturesomely
threatened to cross the fateful threshold into the actual regulation
of medical practice, the political pushback, led by the medical
profession, has been so intense that the FDA has beat a swift
retreat.”); see Teo, supra note 35, at 311.
388. Klasmeier & Redish, supra note 10, at 322 (citing 37 Fed. Reg.
16,503 (Aug. 15, 1972)).
389. Id. at 323.
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failed proposal had represented any real threat to the doctor’s
autonomy in prescribing decisions.390
In 1991, FDA issued a Notice of Intent to withdraw certain
proposed rules for which no final rule or notice of withdrawal had
been issued; among the rules in the notice was the one regarding
restrictions on prescription of certain drugs for uses unapproved
by FDA.391 Months later, FDA determined that it would not
withdraw that particular proposed rule but also would not
proceed to a final rule.392 FDA noted that it had established an
“Unlabeled Use Task Force” to examine promotion and use of
prescription drugs for non-approved indications and stated that
FDA would delay considering the withdrawal of the proposed
regulation until sometime after the task force had completed the
review.393 Based on extensive legal research, it appears that
nothing came of this task force. Further, there is no mention of
subsequent activities in any of FDA’s public communications or
in the scholarly legal literature.
C. Putting the Public Health Before the Healthcare Professional

States regulate medical practice, and physician groups hold
dear the autonomy of their members to practice medicine based
on best judgments. There are instances, however, where a state
is not able to adequately regulate a given space or profession.
When considering whether or not to wield federal power,
Congress and federal agencies should ask whether a given activity
implicates national public health concerns that are beyond the
scope of what individual states properly can address.394 Some
scholars argue that “Article I, Section 8 [of the U.S. Constitution]
empowers Congress to enact those policies that individual states
are structurally ill-suited to resolve as a result of interstate

390. This 1982 “drug bulletin” issued by FDA emphasized that the
Agency regarded off-label use as “accepted medical practice.” Id.
n. 38 (citing Use of Approved Drugs for Unlabeled Indications, 12
FOOD & DRUG ADMIN. DRUG BULL. 4, 5 (Apr. 1982)); see Zettler,
supra note 55, at ns. 71, 72.
391. Berry, supra note 16, at 10 (citing 56 Fed. Reg. 42,668-43,701
(1991)).
392. Id. (citing 56 Fed. Reg. 67,440 (1991)).
393. Id. (citing 56 Fed. Reg. 67,442 (1991)).
394. Zettler, supra note 55, at 432.
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externalities.”395 Where activities are beyond the capacity of
individual states to regulate, federal authority is appropriate and
permissible.396 While the narrative continues that medical practice
is an individualized and local endeavor, medical practice
contributes “to problems that cross state boundaries and require
nationally coordinated or uniform solutions.”397 The widespread
prescription of antipsychotics in the nonpsychotic patient
population is a serious threat to our nation’s public health, and
setting parameters on the sale, prescription and use of
antipsychotic drugs is a national concern that crosses state lines.
1.

Progress in the Works on Federal Level

There is some interest within the federal government to
address the unbridled use of antipsychotics in the nonpsychotic
patient population. While federal studies and initiatives do not
extend to the private health-insurance market or to psychiatric
treatment paid for by patients out-of-pocket, they provide a
starting point.
One federal initiative, The Centers for Education and
Research on Therapeutics (CERTs), conducts research and
provides education to advance optimal use of drugs, medical
devices, and biological products.398 Funded and run as a
395. Leslie Meltzer Henry & Maxwell L. Sterns, Commerce Games and
the Individual Mandate, 100 GEO. L. J. 1117, 1121–22 n.11 (2012)
(citing Neil Siegel, Free Riding on Benevolence: Collective Action
Federalism and the Individual Mandate, 75(3) L. & CONTEMP.
PROBS. 29 (2012)).
396. See KATHRYN ARMSTRONG & JENNIFER STAMAN, CONG. RESEARCH
SERVS., R43609, ENFORCEMENT OF THE FOOD, DRUG, AND
COSMETIC ACT: SELECT LEGAL ISSUES 7 (2018) (noting the FDCA’s
“requirement that articles be in interstate commerce poses ‘no
obstacle’ to FDA enforcing the Act with respect to seemingly
wholly intrastate activities.”).
397. Zettler, supra note 55, at 479.
398. U.S. DEP’T HEALTH & HUM. SERV., AGENCY FOR HEALTHCARE
RESEARCH AND QUALITY: FY 2012 ONLINE PERFORMANCE
APPENDIX (2012). The CERTs receive funds from both public and
private sources, with AHRQ providing core financial support. The
research conducted by the CERTs program has three major aims:
(1) increase awareness of both the uses and risks of new drugs and
drug combinations, biological products, and devices, as well as of
mechanisms to improve their safe and effective use; (2) provide
clinical information to patients and consumers; health care
providers; pharmacists, pharmacy benefit managers, and
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cooperative agreement by the Agency for Healthcare Research
and Quality (AHRQ), in consultation with FDA, the program has
six research centers and a CERTs Scientific Forum.399 In 2010,
sixteen States, the Rutgers University Center for Education and
Research on Mental Health Therapeutics, and Medicaid Medical
Directors Learning Network (MMDLN) collaborated on a report
titled “Antipsychotic Medication Use in Medicaid Children and
Adolescents: Report and Resource Guide From a 16-State
Study.”400 This report contains data on utilization patterns and
treatment practices that raise clinical concerns, including
“polypharmacy, wrong dosages, and the prescribing of
antipsychotic drugs to very young children.”401
In 2011, the OIG commissioned a study regarding
prescription of antipsychotics to Medicaid-covered children to
ensure the quality of care provided to children receiving
SGAs.402As a result, in 2015 the OIG made three
recommendations to CMS, the agency that partially funds State
Medicaid programs. The OIG recommended that CMS work with
State Medicaid programs to (1) perform utilization reviews of
SGAs prescribed to children; (2) conduct periodic reviews of
medical records associated with claims for SGAs prescribed to
children; and, (3) consider other methods of enhanced oversight

purchasers; health maintenance organizations (HMOs) and health
care delivery systems; insurers; and government agencies; (3)
improve quality while reducing cost of care by increasing the
appropriate use of drugs, biological products, and devices and by
preventing their adverse effects and consequences of these effects
(such as unnecessary hospitalizations). Id. at 32–33.
399. Id. at 33.
400. OEI-07-12-00320, supra note 263, at 5. The Rutgers group and
MMDLN receive funding from the Agency for Healthcare Research
and Quality. The 16 collaborating states were Alabama, California,
Colorado, Illinois, Indiana, Maine, Massachusetts, Missouri, New
Hampshire, New York, Oklahoma, Oregon, Pennsylvania,
Tennessee, Texas, and Washington. States prominently featured in
the study were California, Illinois, New York, and Texas.
401. Id.
402. Id. at 31.
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of SGAs prescribed to children, such as implementing peer-review
programs.403 CMS concurred with these recommendations.404
The OIG intervention could influence prescribing practices
because it affected reimbursement policy. Specifically, the
influence derived from the policies that: (1) “[a]ll State Medicaid
programs cover outpatient prescription drugs,” provided that said
outpatient drugs are prescribed for medically accepted
indications;405 and (2) State Medicaid programs may pay for
outpatient drugs not prescribed for medically accepted
indications.406 The Social Security Act defines “medically accepted
indications” as FDA-approved uses and off-label uses supported
in one of the compendia.407 At the time of the OIG review,
only one of the SGAs prescribed to children—risperidone—had
“medically accepted” indications for use in pediatric patients
beyond what FDA had approved.408 Now there are more
antipsychotics designated to have “medically accepted
indications” for use in children, but still the list of indications is
far narrower than uses in actual practice.409 Given the alarming
403. Id. at 32–33.
404. Id.
405. Id. at 2 (citing the Social Security Act, Pub. L. 89-97, 79 Stat. 286,
§ 1905(a)(12) (1965)); Prescription Drugs, MEDICAID.GOV (May
12, 2014), http://www.medicaid.gov/Medicaid-CHIP-ProgramInformation/ByTopics/Benefits/Prescription-Drugs/PrescriptionDrugs.html [https://perma.cc/D8AN-MGBB]; see United States ex
rel. Polansky v. Pfizer, Inc., 822 F.3d 613, 615 (2d Cir. 2016) (citing
42 U.S.C. § 1396r-8(d)(1)(B)(i) (2018)).
406. OEI-07-12-00320, supra note 263, at 5.
407. Id. (citing § 1927(g)(1)(B)(i)(I)–(III) of the Social Security Act).
The three compendia are (1) the American Society of Health
System Pharmacists, Inc.’s American Hospital Formulary Service
Drug Information, (2) the United States Pharmacopeia—Drug
Information (or its successor publications), and (3) DrugDEX
Information System. See 42 U.S.C. §§ 1396r-8(k)(2), (3), (6),
1395w-102(e)(1), (4) (2018).
408. Id. n.10 (“Medically accepted indications for risperidone include its
FDA-approved uses as well as its use to treat (1) behavioral
syndrome-mental retardation and (2) pervasive developmental
disorder.”).
409. CTRS. FOR MEDICARE AND MEDICAID SERVS., ATYPICAL
ANTIPSYCHOTIC MEDICATIONS: USE IN PEDIATRIC PATIENTS 1, 2
(Oct. 2015), available at https://www.cms.gov/MedicareMedicaid-Coordination/Fraud-Prevention/Medicaid-Integrity-
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number of Medicaid-recipient children prescribed antipsychotics
off-label, it appears that government reimbursement practices are
lenient and lacking in oversight.
While federal Medicaid requirements governing the
prescribing of SGAs to children are deficient, federal and state
agencies and professional associations, such as the American
Academy of Child and Adolescent Psychiatry, the National
Committee for Quality Assurance, and the Administration for
Children and Families, have provided guidance and information
on prescribing these drugs to child-patients.410 In 2012, the
Administration for Children and Families released a
memorandum titled “Promoting the Safe, Appropriate, and
Effective Use of Psychotropic Medication for Children in Foster
Care.”411 This memorandum spotlighted three “outlier practices”
that could signify red flags of inappropriate physician prescribing
practices of SGAs: (1) prescribing multiple drugs concurrently
with the antipsychotic; (2) prescribing dosages that are too high;
and, (3) prescribing SGAs to very young children.412
Hope for economically disadvantaged nonpsychotic patients
of all ages who indiscriminately (and perhaps automatically, with
little forethought) are prescribed antipsychotics, may rest in
future Medicaid reimbursement policies. As of December 2019,
Education/Pharmacy-Education-Materials/Downloads/atypantipsych-pediatric-factsheet11-14.pdf
[https://perma.cc/UJ77SA5R]. As of October 2015, six atypical antipsychotics had FDAapproved indications for use in children and adolescents:
aripiprazole, asenapine, olanzapine, paliperidone, quetiapine, and
risperidone, for various combinations of Tourette’s disorder,
schizophrenia, Bipolar I disorder, and irritability with autistic
disorder. Id.
410. Id. at 3; OEI-07-12-00320, supra note 263, at 4 n.14 (“The guidance
discussed here covers all psychotropic drugs—a category that
includes SGAs and several other types of drugs. Other classes of
psychotropic drugs include attention deficit/ hyperactivity disorder
(ADHD) drugs, antianxiety drugs, antidepressants, first-generation
antipsychotics, hypnotics, and mood stabilizers. This study focuses
specifically on SGAs.”)
411. Id. (citing ACF, PROMOTING THE SAFE, APPROPRIATE, AND
EFFECTIVE USE OF PSYCHOTROPIC MEDICATION FOR CHILDREN IN
FOSTER CARE, LOG NO. ACYF-CB-IM-12-03 (Apr. 11, 2012),
available at http://www.acf.hhs.gov/sites/default/files/cb/im1203
.pdf [https://perma.cc/U65A-GJAX]).
412. Id. at 4–5.
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over 71.6 million individuals were enrolled in Medicaid and the
Children’s Health Insurance Program (CHIP).413 This is a sizable
population that can benefit from federal oversight in this area.
CMS determines what services and treatments are “reasonable
and necessary,” and with regard to the elderly and disabled,
Medicare is supposed to reimburse only for those services that are
deemed “reasonable and necessary.”414 These payors could change
their policies, for example by hinging reimbursement for off-label
antipsychotic drugs on a requirement that manufacturers
demonstrate safety and efficacy—evidence of reasonableness and
necessity—through rigorous studies.415
The federal government may also legally impose certain limits
on health-care practitioners who are paid through Medicare and
Medicaid.416 But, as discussed above, the majority of psychiatrists
in the U.S. do not accept either Medicare or Medicaid; and some
do not accept insurance at all.417 It is quite possible, however, that
studies and recommendations like those done by the GAO in 2011
and OIG in 2015, with regard to child Medicaid recipients and
off-label antipsychotic prescriptions, could be applicable to
Medicare recipients in a less direct way. The total number of U.S.
citizens covered by Part D Medicare coverage, including stand413. December 2019 Medicaid & CHIP Enrollment Data Highlights,
MEDICAID.GOV,
https://www.medicaid.gov/medicaid/programinformation/medicaid-and-chip-enrollment-data/report-highlights/
index.html [https://perma.cc/4LCY-NFNF] (last visited Apr. 6,
2020).
414. Zettler, supra note 55, at 470–71 (citing 42 U.S.C. § 1395g (2018))
and 42 U.S.C. § 1395nn (2018)).
415. Joshua Wallach & Joseph Ross, Gabapentin Approvals, Off-Label
Use, and Lessons for Postmarketing Evaluation Efforts, 319
J.A.M.A. 776, 777 (2018).
416. Id.; See also Ass’n of Am. Physicians & Surgeons v. Weinberger,
395 F. Supp. 125 (N.D. Ill. 1975), aff’d sub nom, Ass’n of Am.
Physicians & Surgeons v. Mathews, 423 US. 975 (1975) (affirming
a district court holding that setting forth conditions under federal
Professional Standards Review Law for compensating physicians
with federal funds under Medicare and Medicaid did not bar
physicians from practicing their profession and was not so patently
arbitrary and totally lacking in rational justification as to be
violative of due process clause of Fifth Amendment, as there was
no coercion by the government making physicians participate in
the program).
417. See generally Bishop et al., supra note 2.
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alone prescription plans and Medicare Advantage with
prescription drug coverage, was 39,246,296 as of May 2015.418
While it may be a viable solution to have the federal government
impose limits on medical practice,419 history suggests that the
strong physician lobby would adamantly and effectively oppose
such an agenda. At this point in time, it is widely accepted that
federal agencies such as FDA and HHS cannot interfere with the
practice of medicine; that is relegated to the states.420 HHS,
however, through CMS, can restrict prescription coverage.421
While a doctor is free to prescribe an antipsychotic off label
to a nonpsychotic patient, the government does not need to pay
for that prescription. While the compendia have strong influence
on reimbursement of off-label claims, “there is no strict legal
requirement that these uses be reimbursed under current CMS
rules and regulations.”422 Were CMS to refuse to pay for these
drugs, this would be a powerful way for the federal government
to impose restrictions on the use of antipsychotics without
directly interfering with the practice of medicine.
Federal oversight in this area would not automatically
preempt all state oversight.423 In circumstances of both national
public-health concerns and inadequate state oversight, a limited
proposal can provide a solution to expand “federal options for
addressing public health problems, avoiding ineffective federal
interference with medical practice, and preserving wellfunctioning state regulation consistent with federalism values.”424
418. On Its 50th Anniversary, more than 55 Million Americans Covered
by Medicare, CTRS. FOR MEDICARE & MEDICAID SERVS. NEWSROOM
(July 28, 2015), https://www.cms.gov/newsroom/press-releases/its
-50th-anniversary-more-55-million-americans-covered-medicare
[https://perma.cc/D2EB-MFFB].
419. Zettler, supra note 55, at 480–81.
420. Since the late 1800s, the U.S. Supreme Court has recognized a
state’s right to exercise its police powers in regulating the practice
of medicine. See Dent v. West Virginia, 129 U.S. 114, 128 (1889).
421. See Todd, supra note 95, at 434–45.
422. Paczynski et al., supra note 293, at 143.
423. Zettler, supra note 55, at 482 (citing GOSTIN, supra note 348, at 4);
see also COMM. FOR THE STUDY OF THE FUTURE OF PUBLIC HEALTH,
INST. OF MED., THE FUTURE OF PUBLIC HEALTH 3 (1988);
Onyebuchi A. Arah, supra note 348, 235.
424. Zettler, supra note 55, at 482.
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As federal government oversight in the area would be in stark
contrast with existing schemes, such regulation may serve to
spotlight that area’s significance in public health and educate
physicians and patients about increased risks or need for
vigilance.425
The federal government response to the Opioid epidemic
provides a good example of HHS stepping in, attempting to
regulate a pharmaceutical public-health disaster that is spiraling
out of control. In mid-2016, after two days of hearings, FDA’s
Drug Safety and Risk Management Advisory Committee
recommended that physicians be required to complete specialized
training in order to be able to prescribe Opioids.426 While FDA is
not required to follow or implement advisory-panel
recommendations, it often does so.427 This particular mandate,
however, could not simply be accomplished through the
regulatory process, but would require congressional action.428
Given the current political climate that opposes regulation of any
sort,429 the likelihood of FDA moving forward with the
recommendations is slim. In a different political climate, however,
perhaps a similar plan of attack could be implemented by HHS
to address the problem of antipsychotic use in the nonpsychotic
patient population.430
425. Id. at 488–89.
426. Stephen Loiaconi, Physicians Warn Mandatory Opioid Prescription
Training Could Have Unintended Effects, WJLA (May 5, 2016),
http://wjla.com/news/nation-world/physicians-warn-mandatoryopioid-prescription-training-could-have-unintended-effects
[https://perma.cc/3U6P-EF2T].
427. Id.
428. Id. (“Despite a similar expert panel recommendation in favor of
mandatory training in 2012, the FDA had opted to make
educational courses on safe pain prescription voluntary. As of
March 2015, less than half of the 80,000 doctors the agency wanted
to complete that training had done so.”).
429. See Kathy Wagner Hill, The State of the Administrative State: The
Regulatory Impact of the Trump Administration, 6 EMORY CORP.
GOV’T & ACCOUNTABILITY REV. 25, 26–7 (2019).
430. Interestingly, the Substance Abuse and Mental Health Services
Administration (“SAMHSA”), an agency within the U.S. HHS that
leads public health efforts to advance the behavioral health of the
nation, and whose mission is to reduce the impact of substance
abuse and mental illness on America’s communities, advocates for
shared decision-making. On the SAMHSA website is a link to an
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2.

Reform at State Level—What Could be Done?

States are in a unique position to foster needed changes in
the prescribing habits surrounding antipsychotics in the
nonpsychotic patient population. A desire to keep citizens healthy
while keeping down costs should incentivize states to seriously
consider options for intervention, which may include State
Medicaid policy adjustments. Other areas of influence include
state legislation and regulation, and the ability of a state to
modify physician practices through physician state-licensing
boards. Other options are for states to explicitly define what is
experimental in medical practice, and how that must be disclosed
to patients. It may require some creativity to identify what will
work in a particular state, and how implementation of new policy
should proceed, but a state-based solution to harms caused by
off-label prescription of antipsychotics, where FDA refuses to
intervene, may be one of the best options available for realizing
meaningful change and reform.
a.

State Medicaid Services

State Medicaid Services have a compelling interest in
preventing the needless adverse side effects stemming from
unnecessary use of antipsychotics in the nonpsychotic patient
population. The adverse side effects that can and do result from
use of antipsychotics contribute to increased healthcare claims for
avoidable physical illnesses directly caused by antipsychotics.
Physicians should be provided disincentives for unnecessarily
prescribing antipsychotic drugs, and should be held accountable
through refusal of payment where Medicaid determines there is a
lackadaisical attitude in the physician’s prescribing practices.
In the 2015 OIG report, insufficient or non-existent
monitoring was the most common quality-of-care issue, identified
in more than half of claims for SGAs prescribed to Medicaid
recipient children.431 As a result, the OIG recommended that CMS
online tool ”Considering the Role of Antipsychotic Medications in
My Recovery Plan” for people using or seeking treatment services
involving antipsychotic medications, with recommendations on how
to speak to one’s doctor about the use of antipsychotics in
treatment. Considering the Role of Antipsychotic Medicine,
SAMHSA, https://www.samhsa.gov/brss-tacs/recovery-supporttools/shared-decision-making [https://perma.cc/C5SW-H765] (last
visited Mar. 27, 2020).
431. OEI-07-12-00320, supra note 263, at 12.
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work with State Medicaid programs to perform utilization reviews
of SGAs prescribed to children, focusing on the children’s ages,
duration of their treatment with SGAs, and their overall drug
regimens.432 The OIG review criteria could be useful in crafting
state guidelines. Specifically, conducting periodic reviews of
medical records associated with claims for SGAs prescribed to
children to ensure: (1) clear rationales exist for prescribing the
SGAs; (2) patients are being properly monitored; and (3)
children’s dosages are properly adjusted.433 The OIG also
encouraged states to consider other methods of enhanced
oversight of SGAs prescribed to children, including implementing
peer-review
programs
(through
which
prescribers
encourage one another to improve quality of care) and
undertaking voluntary reporting of the Healthcare Effectiveness
Data and Information Set (HEDIS)434 measures regarding
children’s use of antipsychotic drugs or adopting the HEDIS
measures in State oversight of SGAs.435
These same guidelines could be extended to adult recipients
of State Medicaid services who are not suffering from psychoses
but nonetheless are prescribed antipsychotics off label. And the
extension of policies to the adult Medicaid population could then
be a model for new standards of care in the private sector. The
2015 OIG report is a rich and readily available resource, and its
thoughtful recommendations could be put to use beyond the
original focal population.
b.

Other Ideas for State Influence in Addressing Problem

States could enact laws requiring specific informed consent
for off-label prescription of antipsychotics, especially prescriptions
to nonpsychotic patients. Nonpsychotic patients would benefit
432. Id. at 15 (“The previously described guidance and information on
using SGAs to treat children—such as the utilization guidelines
developed by the Florida and Texas Medicaid programs— may be
of use to CMS and to other State Medicaid programs in developing
guidelines for such utilization reviews.”).
433. Id.
434. HEDIS and Performance Measurement, NAT’L COMM. QUALITY
ASSURANCE, https://www.ncqa.org/hedis/ (last visited Dec. 7,
2018)
[https://perma.cc/6SNX-DGTZ]
(“The
Healthcare
Effectiveness Data and Information Set (HEDIS) is one of health
care’s most widely used performance improvement tools.”).
435. OEI-07-12-00320, supra note 263, at 15.
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from playing a larger role in decision-making (even by guardians
or surrogates) regarding the use of antipsychotics. This may be a
critical juncture for treatment decision-making in that long-term
adverse side effects might be put into motion, and in some
instances be irreversible.
Some states, through legislation, have delineated the general
disclosure required in certain procedures and treatments, but
physicians have not been given any clear directive as to precisely
what must be disclosed to patients.436 Even in these states,
because the medical community sets its own standards within the
practice of medicine, physicians still are given latitude in deciding
what information to disclose to patients.437 States could require
more, directly through their statutes, or through mandates to
medical- and psychiatric-licensing boards.
Closer and systematic attention to informed consent and
decision-making is required in the context of medical practice.438
Alone, intent to benefit the patient does not supply sufficient
justification for an intervention, regardless of whether it is called
research, innovation, or treatment.439 Consent-related discussions
regarding the nature, magnitude, and likelihood of benefit—in
both standard and innovative treatment—are quite often
insufficient.440 Individuals (patients, parents, or guardians) faced
with difficult decisions need information about expected benefits
and the sources of information that allegedly support such
expectations.441 There must be substantial, candid discussion
regarding all likely and possible adverse side effects.
A state’s legislative authority is limited only by the federal
constitution and the state’s constitution.442 Thus, a state
legislature that deems it “appropriate to regulate research beyond
the scope of existing federal regulations is unquestionably free to
do so as an aspect of its sovereign power.”443
A proposed
436. Barkus & Derian, supra note 20, at 862.
437. Id.
438. King, supra note 64, at 581.
439. Id.
440. Id. at 582 (footnote omitted).
441. See id. at 581–82.
442. COLEMAN ET AL., supra note 10, at 179 (quoting Township of Pine
Grove v. Talcott, 86 U.S. 666, 676 (1873)).
443. Id.
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California law would have required physicians to inform
patients when prescribing medications off label, thereby alerting
patients to the "experimental" nature of the treatment.444 This
proposed law would have applied to all off-label uses.445 States
should consider the spirit of the proposed California law in crafting
heightened protections for nonpsychotic psychiatric patients,
including the designation of off-label prescription of antipsychotics as
“experimental” and a requirement that physicians engage
patients in meaningful discussions about risks and benefits.
On the other hand, there may be intermediate options that
“involve[e] intraprofessional peer review and consent guidelines,
at the level of a division, department, institution, or professional
association.”446 The OIG recommendations take into
consideration some of these strategies in implementing controls in
the prescription of antipsychotic drugs to the nonpsychotic-child
Medicaid recipient.447 This approach can be extended to and
modeled by state medical- and psychiatric-licensing boards.
Through legislation, regulation, and medical-licensing boards,
a state can regulate what is required of physicians within that
state’s borders. More stringent informed consent requirements
will alert a nonpsychotic psychiatric patient that the
antipsychotic their doctor is about to prescribe has not been
proven safe or effective for a given condition. By arming the
patient with knowledge, and requiring a meaningful conversation
between doctor and patient, the state may substantially influence
decisions regarding off-label use of antipsychotics.
c.

States Can Impose Regulations on Non-Federally-Funded
Clinical Research

State protections may exceed those set by
federal
law, and what is not clinical research
according
to FDA can
be
deemed
“ experimental”
Another
area
open
for
state
by a
state.
regulation is clinical research that is not (1) conducted or
funded by agencies that have adopted the Common Rule;448
(2) under FDA’s exclusive
444. Assemb. B. 2856, 2005-2006 Reg. Sess. (Cal. 2006).

445. Id.
446. King, supra note 64, at 576 (footnote omitted).
447. OEI-07-12-00320, supra note 263, at 16.
448. See 45 C.F.R. § 46 (2019).
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jurisdiction; or (3) conducted at an institution that has agreed,
in an assurance to the Office for Human Research Protections,
that all research at the institution will be conducted in line with
the Common Rule.449 Privately funded research is generally
outside the purview of federal government regulation, which
means the federal government cannot know the number of
Americans who are subjects in private research, influence subject
recruitment practices, ensure that research subjects are informed
of risks, or ascertain if these subjects suffer harm.450 Among
venues listed by the National Bioethics Advisory Commission
where non-government funded research could take place and
where federal regulation has no force are private offices of some
physicians and psychotherapists.451
Clearly, state law is relevant to the research enterprise, and
states can regulate privately funded research or any other
activities within their borders.452 For research endeavors not
falling within federal jurisdiction, “state law (if any) becomes the
only legally applicable regulatory regime.”453 When federal law
does apply to research, it expressly preserves any additional state
protections. For example, the Common Rule specifically addresses
preemption: “[t]his policy does not affect any state or local laws
or regulations (including tribal law passed by the official
governing body of an American Indian or Alaska Native tribe)
that may otherwise be applicable and that provide additional
protections for human subjects.”454
Further, under the Common Rule, informed consent
requirements “are not intended to preempt any applicable
Federal, State, or local laws which require additional information
to be disclosed in order for informed consent to be legally
effective.”455 Preserving a role for states in research regulation is
449. COLEMAN ET AL., supra note 10, at 178.
450. Id. at 178 (quoting the Nat’l Bioethics Advisory Comm’n).
451. Id. at 176.
452. Id. at 179.
453. Id. at 178 (quoting JACK SCHWARTZ, OVERSIGHT OF HUMAN
SUBJECT RESEARCH: THE ROLE OF THE STATES IN NATIONAL
BIOETHICS ADVISORY COMMISSION; ETHICAL AND POLICY ISSUES IN
RESEARCH INVOLVING HUMAN PARTICIPANTS § 3.05 (2001)).
454. Id.; see Revised Common Rule, 45 C.F.R. Pt. A § 46.101(f) (2019).
455. COLEMAN ET AL., supra note 10, at 178.
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wholly appropriate given that one of a state’s core functions is to
protect its citizens—including human subjects—from harm.456
While this may result in greater variability in clinical research
requirements, which may complicate implementation of multisite
studies, state interpretations of what constitutes research and
what informed consent must include provide potential avenues
for states to step in and offer protections to the scores of
nonpsychotic psychiatric patients who are prescribed
antipsychotics off label.
Besides delineating the scope of medical practice, licensing
requirements, and medical board disciplinary power, states may
regulate medical practice in a multitude of manners.457 California,
for example, requires physicians to distribute to patients
standardized pamphlets regarding blood transfusions, breast
cancer, gynecological cancers, silicone implants, prostate cancer,
and patients’ rights and remedies if they have been in a sexual
relationship with their therapist.458 States may also impose
requirements for specific procedures and the timeframes in which
they must be performed, for example, treating infants with
eyedrops immediately, within an hour, or within two hours of
birth.459 Also, each state has mandated newborn medical screening
tests to detect genetic and metabolic disorders, but the specific
mandates vary by state.460 States could require certain screening
456. Id.; see Panhandle Eastern Pipe Line Co. v. St. Highway Comm’n,
294 U.S. 613, 622 (1935) (“It springs from the obligation of the
state to protect its citizens and provide for the safety and
good order of society. Under it there is no unrestricted authority to
accomplish whatever the public may presently desire. It is the
governmental power of self-protection and permits reasonable
regulation of rights and property in particulars essential to the
preservation of the community from injury”).
457. Zettler, supra note 55, at 451.
458. Id. at 452 (citing MED. BD. OF CAL., GUIDE TO THE LAWS
GOVERNING THE PRACTICE OF MEDICINE BY PHYSICIANS AND
SURGEONS 70–71 (7th ed. 2013), available at http://perma
.cc/K3WB-YHSK).
459. Id. (citing N.H. REV. STAT. § 132:6 (2006)); MICH. COMP. LAWS
ANN. § 333.5125 (West 2001); MASS. GEN. LAWS ANN. ch. 111,
§ 109A (West 2003)).
460. Id. (citing About Newborn Screening: Conditions Screened by State,
BABY’S FIRST TEST, http://www.babysfirsttest.org/newbornscreening/states [http://perma.cc/9RNC-BG4H] (last visited Feb.
18, 2020) and Jennifer Kraszewski et al., Legal Issues in Newborn
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procedures to determine whether use of an antipsychotic would
be the best first-, second- or third-line defense in treating the
nonpsychotic patient. States could also require physician
education hours on the topic of using antipsychotics in the
nonpsychotic patient population and channel resources to
awareness-raising campaigns.
States have many underutilized tools to shape policies and
practices relating to off-label prescription of antipsychotics to
nonpsychotic patients. States could get out ahead of the
escalating off-label prescription of antipsychotics by recalibrating
the parameters for (1) provision of publicly funded psychiatric
services (making psychotherapy less costly or free); (2)
reimbursement policies under State Medicaid (making
reimbursement contingent on evidence-based justifications for
treatments, including prescription of off-label antipsychotics);
and (3) determining what is appropriate and acceptable medical
practice in the context of nonpsychotic psychiatric patients
(influencing psychiatrists’ prescribing practices and consideration
of alternative methods). By doing so, states could wield
substantial influence in treatment decisions and improve
outcomes for many individual patients.

Conclusions and Thoughts on Future Efforts
Illuminating the incidence of inappropriate and harmful offlabel prescription of antipsychotic drugs and their indiscriminate
use in the nonpsychotic patient population may also depend on
efforts of consumer advocacy groups and media reports. In order
to accurately portray this as a valid concern for all mental-health
patients in the U.S., it would be prudent to enlist the support of
liberal, mainstream, and conservative groups and news outlets
alike. The media could play a critical role in spotlighting this
mostly under-the-radar issue. If the public knows that
antipsychotic use is frequent in the nonpsychotic population, and
oftentimes not in patients’ best interests, public opinion could
influence the way doctors conduct the practice of medicine.
Lobbying efforts at the individual state level will be required to
Screening: Implications for Public Health Practice and Policy, 121
PUB. HEALTH REP. 92, 92–93 (2006), available at http://
www.publichealthreports.org/issueopen.cfm?articleID=1585 [http:
//perma.cc/QMF9-GY63] (discussing the legal issues raised by
state newborn screening programs)).
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effect any sort of meaningful change in how antipsychotics are
prescribed to nonpsychotic patients and to frame the issue of
what oversights should be established through state statutory
mandates, then implemented by medical and psychiatric boards.
While it is heartening to see that there are both federal and
state government agencies aware of the problems associated with
antipsychotic use in the nonpsychotic patient population, and
that studies and some guidance have been undertaken, followthrough with purposeful, meaningful action is needed. Further,
much more must be done to reach and advocate on behalf of the
millions of patients who pay solo practice psychiatrists out-ofpocket for treatment. Private health-insurance companies must
question prescriptions and restrict payment/reimbursement.461
That alone would have a negative effect on the nonpsychotic
patient’s pocketbook and might spur discussion between the
patient and psychiatrist regarding the off-label nature of the
prescription and the evidence of safety and efficacy—or lack
thereof.
Efforts to address widespread off-label use of potentially
harmful antipsychotics are the responsibility of many, including
physicians, government regulators, policy makers and advisors,
public health experts, scholars, politicians, payors, drug
manufacturers, the media, and patients and their advocates; but,
it is physicians who “‘wield the prescribing pen.’”462 Medical
associations and boards strongly resist efforts of non-physicians
to participate in discussions regarding off-label prescriptions, but
in performing their duty to self-regulate, these medical
professionals are falling short. Therefore, invited or not, more
people must enter the off-label-prescription conversation, and
change it.

461. In their recent study, Vijay et al., found that private insurance was
billed for 41.3% of the psychiatric- patient appointments in their
study sample. There is a large group of patients that will not be
reached by changes in CMS coverage decisions. Vijay et al., supra
note 324, at 5.
462. Joshua Wallach & Joseph Ross, Reply to Karen Maschke: Off-Label
Use of Medications, 320 JAMA 306, 307 (2018).
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